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Abstract 
BACKGROUND: Breast cancer patients typically present with impaired glucose 
metabolism at diagnosis. Given that increased fat mass and decreased lean mass develop 
throughout the treatment trajectory and into survivorship, these impairments in glucose 
metabolism may worsen and may increase the risk of breast cancer patients developing 
secondary diseases such as diabetes in survivorship. Aerobic and resistance exercise 
training are known to improve glucose regulation in various clinical populations, but this 
has not been comprehensively explored in breast cancer patients.  
OBJECTIVES AND HYPOTHESES: The primary objectives of this study were to: 1) 
examine the differences in glucose and related markers, as well as potential explanatory 
measures such as body composition, inflammatory markers, aerobic capacity, muscular 
strength, and dietary intake between a heterogeneous group of breast cancer patients and 
a group of young healthy females, and 2) evaluate the potential changes in these 
collective measures in breast cancer participants following 24 one hour sessions of a 
combined cardiovascular and strength training program. Secondary objectives were to: 1) 
examine potential effects of the time to complete 24 one hour sessions on metabolic 
parameters and 2) evaluate baseline measures of the breast cancer group that dropped out 
to those that completed the exercise program to identify potential bias in the group that 
completed the exercise program. We hypothesized that breast cancer participants, prior to 
exercise training, would present with poorer glucose concentrations and related markers, 
body composition, inflammatory markers, aerobic capacity, muscular strength, and 
dietary intake in comparison to the healthy young reference group. We also hypothesized 
that all measures would improve with the exercise program and that dietary intake would 
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remain the same. Additionally, we anticipated that patients who completed the 24 
exercise sessions in a shorter time-frame would exhibit greater improvements in glucose-
related parameters compared with those who took longer to complete the program. 
Baseline measures between breast cancer exercise completers were expected to be similar 
to those that dropped out of the program.  
METHODS: Breast cancer patients, at any stage of disease, any phase of treatment and 
any treatment time, were recruited to this study. Participants underwent a supervised 
exercise program consisting of 24 1-hour sessions of combined aerobic and resistance 
exercise (usually aerobic training to start followed by resistance training). Attendance of 
two exercise sessions per week for one hour was prescribed. Assessments were done at 
baseline and following the exercise program for the breast cancer patients Baseline 
assessments from the patients were compared with similar measures collected, at a single 
time point, in the young healthy female reference group. We evaluated glucose and 
related markers by biochemical analysis on fasting blood. Body composition was 
assessed by dual energy x-ray absorptiometry (DXA) scans, body mass index (BMI) and 
waist circumference (WC). Cardiovascular capacity in breast cancer patients was 
measured by a graded exercise test and strength was assessed using a predictive one 
repetition maximum (1RM) test on the upper and lower limbs. Dietary intake was 
assessed using 3-day food diaries.  
RESULTS: Prior to exercise training, breast cancer patients presented with higher 
measures of fasting plasma glucose, glycated hemoglobin, IGF-1, insulin and a tendency 
for higher c-peptide when compared to the young healthy reference group; however, 
there were no differences in inflammatory markers between groups. Furthermore, 
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percentage of fat, total fat mass, BMI and WC were elevated in breast cancer patients 
compared with the reference group. Aerobic exercise tests, resting heart rate and 
muscular strength demonstrated poorer results relative to the reference group. Daily 
caloric intake was higher in the reference group but macronutrient distribution was not 
significantly different. Following 24 sessions of combined aerobic and resistance 
training, there were significant reductions in fasting plasma glucose (5.4 ± 0.7 vs. 5.0± 
0.4 mM, p=0.008) and IGF-1:IGFBP-3 (0.33 ± 0.12 vs 0.27 ± 0.09 ng/mL, p= 0.018). 
Homeostatic model assessment for insulin resistance (HOMA-IR) (2.9 ± 2.4 vs. 2.1 ± 1.7 
ng/mL, p= 0.06) tended to improve. IGF-1 and lactate tended to decrease following the 
exercise program as well. Inflammatory markers primarily remained unchanged but a 
significant increase in TNF-α as well as a tendency for increased IL-1β were observed. 
Increasing delta TNF-α  (from baseline to post-exercise program) was correlated with 
increasing delta of total fat mass (r= 0.908, p=0.0124, n= 6). Cardiovascular capacity, 
resting blood pressure as well as lower limb muscular strength improved following the 
exercise program. There were no changes in dietary intake during the exercise program. 
No differences were identified between the breast cancer dropout group and the breast 
cancer group that completed the exercise program. 
DISCUSSION AND CONCLUSIONS: Breast cancer patients presented with various 
metabolic, body composition, and fitness parameters that were poorer than the young 
healthy reference group. The exercise intervention was associated with improved plasma 
glucose, HOMA-IR and IGF-1:IGFBP-3, suggesting improvements in glucose 
metabolism. Future work needs to further evaluate these improvements and compare 
them with a usual care group that is undergoing treatment but no exercise intervention. 
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1.0 Overview 
Although breast cancer is the most common type of cancer, the success of diagnostic 
tools and treatment regimens have led to an impressive five-year survival rate of 88% (Canadian 
Cancer Society, 2015). Despite these advances in detection and treatment, knowledge about  
metabolic changes (i.e. development of glucose intolerance, insulin resistance) that accompany 
patients throughout the treatment trajectory is limited. Though literature to date primarily focuses 
on insulin resistance and risk of diabetes development in breast cancer survivors (Bordeleau et 
al., 2011; Ligibel et al., 2008; Lipscombe et al., 2013), signs of insulin resistance and 
impairments in glucose metabolism have also been shown in patients near diagnosis and during 
treatment (Bell et al., 2013; Can et al., 2013; Goodwin et al., 2009; Lu et al., 2014). Impairments 
in glucose metabolism increase the risk, not only for development of secondary diseases such as 
diabetes and cardiovascular disease, but also increase the risk for breast cancer recurrence and 
death (Erickson et al., 2011; Goodwin et al., 2002; Yerrabothala et al., 2014).   
Breast cancer patients undergoing treatment often experience gains in fat mass during this 
period and into survivorship (Aslani et al., 1999; Campbell et al., 2007;  Demark-Wahnefried et 
al., 2001; Demark-Wahnefried et al., 2004; Harvie et al., 2004). Obesity in non-malignant 
populations is related to glucose dysregulation (Amati et al., 2009). Uniquely, breast cancer 
patients have also shown decreases in lean mass in addition to the gain in fat mass (Cheney et al., 
1997; Demark-Wahnefried et al., 2001; Demark-Wahnefried et al., 2002; Freedman et al., 2004; 
Harvie et al., 2004), which has important implications since skeletal muscle is responsible for 
~85% of whole body glucose disposal (DeFronzo et al., 1981). Collectively, body composition 
features and changes in these compartments may relate to deleterious changes in glucose 
handling during the treatment, and overall, disease trajectory. 
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 Several factors need to be evaluated that affect glucose handling that alter during the 
cancer trajectory: inflammation, diet and physical activity. Pro-inflammatory cytokines are 
generally elevated in breast cancer patients (Kozłowski et al., 2003; Lee et al., 2003; Pierce et al., 
2009; Plomgaard et al., 2005; Rivas et al., 2008; Salgado et al., 2003), and this has been linked to 
tumour proliferation, metastasis, insulin resistance and decreased rates of survival (Cole, 2009; 
Lee et al., 2003; Pierce et al., 2009; Plomgaard et al., 2005; Rivas et al., 2008). In contrast, other 
studies have shown no significant increase in pro-inflammatory cytokines in breast cancer 
patients (Bell et al., 2013; Pusztai et al., 2004). Caloric intake has been shown to be reduced in 
breast cancer patients during chemotherapy (Demark-Wahnefried et al., 2001); in contrast, 
increased caloric intake mid-way through chemotherapy as well as 3 months following 
completion of treatment have also been found (Harvie et al., 2004). It is likely that changes in 
diet are related to the time in the disease trajectory that diet is recorded during. The methods used 
to record changes in diet are also likely to influence interpretations from study to study. In 
addition, caloric intake needs to be balanced with physical activity. Indeed, breast cancer patients 
with any stage of breast cancer and any type of treatment have higher sedentary behaviour post-
diagnosis (Irwin et al., 2003). This decrease in physical activity has been suggested to promote 
loss of muscle and fat gain (the development of sarcopenic obesity) in patients (Demark-
Wahnefried et al., 2001), and this may occur in absence of changes in caloric intake.  
 Taken together, glucose related markers, body composition, inflammation, and 
energy balance are interconnected and all play a role in breast cancer and the occurrence of 
glucose metabolism impairments (Figure 1.1 and 1.2). By targeting energy expenditure through 
fitness, perhaps some of the deleterious changes shown by previous studies that occur during the 
treatment trajectory can be avoided. To date, no studies have investigated glucose metabolism 
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and factors that may affect it in a comprehensive manner in breast cancer patients that are 
undergoing treatment.  
A balanced diet and physical activity have shown to improve glucose metabolism in non-
malignant populations (Eriksson et al., 1997; Schmitz et al., 2010). To date, studies investigating 
exercise interventions mainly focused on breast cancer survivors and aerobic exercise training 
(Fairey et al., 2003; Guinan et al., 2013; Thomas, et al., 2013). Fewer studies have investigated 
resistance exercise but those that have, found improvements in lean mass which were not 
observed in studies investigating aerobic exercise (Courneya et al., 2007; Schmitz et al., 2005). 
A combination of aerobic and resistance exercise have shown improvements in glucose clearance 
in non-malignant diabetic populations (Cuff et al., 2003). There is only one study that has used 
combined aerobic and resistance exercise in breast cancer survivors but they were able to 
demonstrate improvements in fasting insulin (Ligibel et al, 2008). However, the effects of 
combined aerobic and resistance exercise on glucose metabolism in breast cancer patients who 
are undergoing anti-neoplastic treatment are unknown.  
This thesis examines the effects of a 24-session, mixed aerobic and resistance training 
program on glucose metabolism in breast cancer patients and recent survivors. Measures 
including body composition, diet and inflammatory mediators were examined to understand their 
role on potential changes in glucose metabolism with exercise training in this population.  This 
thesis will advance our understanding of potential metabolic changes that may associate with 
exercise training and will provide the basis for designing future larger-scale, exercise training 
studies.  
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Figure 1.1 Key factors related to impairments in glucose metabolism in breast cancer. All 
measures in the grey circles are factors that may contribute to impairments in glucose 
metabolism. Glucose and related markers are used to measure impairments in glucose 
metabolism. 
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Figure 1.2 Interconnections between different factors contributing to impairments in 
glucose metabolism in breast cancer. The various factors that contribute to impairments in 
glucose metabolism are interrelated (interrelationships are indicated by the dashed lines). An 
increase in circulating glucose concentrations will increase insulin concentrations, which lower 
IGFBP-3 concentrations and thereby increase the amount of bioactive IGF-1. Changes in body 
composition, particularly increases in adiposity, increase various pro-inflammatory markers. 
Decreases in muscular strength can be related to decreases in lean mass and vice versa. Increases 
in caloric intake as well as dietary fat intake can lead to increases in fat mass. All of these factors 
can lead to impairments in glucose metabolism.   
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2.0 Literature Review  
 
2.1 Systemic glucose metabolism impairments in non-malignant populations 
 One in four people in Canada are diabetics, prediabetics or have undiagnosed diabetes 
(Canadian Diabetes Association, 2005). Additionally, 90% of diabetics have type 2 diabetes 
(Canadian Diabetes Association, 2005). This type of diabetes is characterized by a decrease in 
glucose uptake due to insulin resistance, at tissues such as skeletal muscle, and eventually leads 
to elevated circulating glucose concentrations and a state of hyperglycemia (Petersen & 
Shulman, 2006). To compensate for the increase in circulating glucose, the pancreas releases 
more insulin ultimately leading to a hyperinsulinemic state (Petersen & Shulman, 2006). 
Eventually the pancreas can no longer counter hyperglycemia with increasing insulin, resulting 
in progressive beta cell function declines (Kahn, 2001) and reduced numbers of beta cells (Butler 
et al., 2003); with these degradative changes, the pancreas may no longer able to produce 
adequate supplies of insulin (Kahn, 2001). Consequently, insulin-mediated glucose uptake is 
decreased, raising blood glucose levels and resulting in a state of type 2 diabetes. This may not 
be the only mechanism of diabetes. The pancreas could continue to produce insulin, leading to 
increases in circulating insulin as well as increased glucose concentrations due to impaired 
clearance by the muscle. 
 Skeletal muscle constitutes the most important part of glucose clearance seeing as it is the 
largest site of insulin sensitive tissue (Wasserman et al., 2011). Normally, glucose is transported 
via the bloodstream to the muscle. There, insulin binds to an insulin receptor on the muscle 
membrane, initiating a signaling cascade that leads to GLUT4 translocation to the membrane and 
ultimately glucose clearance from the bloodstream (Saltiel & Kahn, 2001). In an insulin resistant 
or diabetic state, insulin signaling is impaired and therefore, increases in circulating glucose 
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concentrations are seen due to the inability of glucose uptake by the muscle (Saltiel & Kahn, 
2001). Another signaling cascade which activates translocation of GLUT 4 occurs through 
muscle contraction, thereby also allowing for muscle glucose uptake without requiring insulin 
signaling (Kennedy et al., 1999; Wasserman et al., 2011). Though skeletal muscle is the largest 
site of glucose disposal, other organs such as the liver are involved as well. Accumulation of fat 
in the liver has been shown to result in hepatic insulin resistance (Samuel et al., 2004). In 
addition to this, during an insulin resistant state, the liver is unable to properly convert glucose to 
glycogen during the postprandial state and increases gluconeogenesis, thereby leading to a 
hyperglycemic state (Savage et al., 2007). Based on this information, it can be presumed that 
liver insulin resistance may precede systemic insulin resistance which also affects glucose uptake 
at skeletal muscles.  
 
2.2 Impairments in glucose metabolism across the breast cancer treatment trajectory 
 Breast cancer patients have shown impairments in glucose metabolism near diagnosis 
(Can et al., 2013; Goodwin et al., 2009; Lu et al., 2014), throughout treatment (Bell et al., 2013; 
E. M. Guinan et al., 2014) and into survivorship (Bordeleau et al., 2011; Ligibel et al., 2008; 
Lipscombe et al., 2013). These impairments can lead to secondary diseases such as diabetes and 
increased risk of cancer recurrence in survivorship (Bordeleau et al., 2011; Erickson et al., 2011; 
Lipscombe et al., 2013; Yerrabothala et al., 2014). Furthermore, impairments in glucose 
metabolism and related markers have been found to increase breast cancer recurrence and 
decrease survival rates (Erickson et al., 2011; Goodwin et al., 2002; Yerrabothala et al., 2014). 
Assessing glucose metabolism in breast cancer patients across the treatment trajectory is an 
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important step in preventing the development of unfavourable changes in glucose or at least 
managing glucose and glucose-related parameters.  
There is limited research evaluating glucose metabolism in newly diagnosed breast 
cancer patients. Hyperinsulinemia was found in newly diagnosed breast cancer patients and 
correlated to insulin resistance as measured by a number of calculations including homeostatic 
model assessment (HOMA) (Goodwin et al., 2009). This aligns with a study that showed a pre-
diabetic state in newly diagnosed patients, confirmed by an oral glucose tolerance test (OGTT), 
in a Chinese breast cancer population, whereby glucose handling was impaired (Lu et al., 
2014).HOMA also demonstrated insulin resistance in another sample of breast cancer patients, 
but it was not associated with prognostic factors such as tumour size (Can et al., 2013). 
Conversely, this pre-diabetic state could progress into diabetes as patients endure treatment.  
Impairments in glucose metabolism have been examined during treatment as well. Even 
at the beginning stages of chemotherapy treatment (1-2 cycles), where some would argue that 
treatment effects would have potentially not taken place yet, basal concentrations of c-peptide 
have been shown to be elevated compared with non-malignant females who were age- and body 
mass index (BMI)- matched as well as a young, healthy, non-malignant group of females (Bell et 
al., 2013). During an OGTT, these patients reached higher concentrations of glucose which, 
along with c-peptide and insulin, remained elevated for a greater period of time in comparison to 
non-malignant matched and young, healthy females (Bell et al., 2013).  It can be presumed that 
insulin was continually released from the pancreas in an effort to clear the elevated glucose from 
the system; implying that glucose clearance may be impaired early in the disease trajectory, 
when treatment-induced metabolic changes were less likely to have occurred (Bell et al., 2013). 
Another cross-sectional study supported these findings by demonstrating that breast cancer 
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patients at diagnosis were pre-diabetic, while those who were undergoing chemotherapy 
treatment (before the 5th or 6th cycle) were found to be diabetic (Lu et al., 2014). Since treatment 
was the only difference between the two groups, it was assumed that chemotherapy was 
associated with this impairment in glucose metabolism. Another group performed a similar study 
that examined glycated hemoglobin (HbA1c), fasting insulin and insulin resistance (as 
demonstrated with the HOMA-IR) in breast cancer patients prior to and following adjuvant 
treatment (including chemotherapy and radiation treatment). With adjuvant treatment, patients 
showed elevated concentrations of fasting insulin, HbA1c as well as insulin resistance (Guinan et 
al., 2014). While there are a few studies that have examined glucose metabolism during the 
treatment trajectory, a large gap remains in terms of understanding the impairments in glucose 
handling that arise during anti-neoplastic treatment.  
Even after completion of treatment, breast cancer patients have been shown to be at an 
increased risk of developing secondary diseases (such as cardiovascular disease and diabetes) in 
survivorship (Bordeleau et al., 2011; Lipscombe et al., 2013; Juanjuan et al., 2015). The onset of 
diabetes may vary depending on the treatment provided. With adjuvant chemotherapy, risk of 
diabetes has been shown to be increased within the first two years post-diagnosis (Lipscombe et 
al., 2013). Interestingly, mutations in Breast Cancer gene 1 and 2 (BRCA 1 and 2), which 
increase the risk of developing breast cancer, may also have a role in contributing to the 
development of diabetes. Women who test positive for gene mutations in BRCA1 or BRCA2 
gene are also likely to develop diabetes within 15 years from diagnosis than those who did not 
develop breast cancer (relative risk, 2.0) (Bordeleau et al., 2011). This further demonstrates that 
breast cancer itself may potentially lead to the development of diabetes. Breast cancer survivors 
still present with elevated insulin levels and insulin resistance as measured by HOMA (Ligibel et 
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al., 2008). Hyperinsulinemia has been shown to increase risk for breast cancer recurrence as well 
as death in both pre- and post-menopausal women with breast cancer (Erickson et al., 2011; 
Goodwin et al., 2002; Yerrabothala et al., 2014). Examining potential contributors to 
deteriorating glucose management during treatment and beyond, including body composition, 
nutrition, inflammation and physical activity, is important. 
 
2.3 Body composition as a potential contributor to glucose metabolism impairments 
In non-malignant populations, obesity, often attributed to an energy imbalance with  
greater energy intake than output, leads to fat accumulation and eventually insulin resistance in 
most individuals. Obese individuals are typically less insulin sensitive than normal weight 
sedentary individuals who are less insulin sensitive than normal weight active individuals (Amati 
et al., 2009).  Obese type 2 diabetics show more fatty acid transporter FAT/CD36 translocation 
to the cell membrane and therefore, allow more fatty acids to enter the muscle and remain in 
storage in the form of triglycerides (Bonen et al., 2004). This increased uptake of triglycerides 
may, ultimately, lead to the formation of lipotoxic intermediates (such as ceramides and 
diacylglycerols) (Goodpaster et al., 2000; Pan et al., 1997). These lipotoxic intermediates are 
believed to block the insulin signaling pathway, thereby contributing to a state of insulin 
resistance.  
 On the other hand, skeletal muscle is the main site for glucose disposal and therefore, a 
decline in muscle quantity would be expected to impair glucose clearance. Even if one is obese, 
low muscularity may have profound effects on glucose management. Sarcopenic obese 
individuals (individuals who were obese and had lower than normal muscle mass) were insulin 
resistant (as measured by HOMA) and had higher percentages of HbA1c compared with non-
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sarcopenic obese individuals (Srikanthan et al., 2010). Interestingly, Srikanthan et al (2010) also 
found sarcopenic, non-obese individuals exhibited insulin resistance.  
These findings in non-malignant populations have interesting implications in breast 
cancer. Weight gain in patients has been shown across the treatment trajectory and into 
survivorship (Harvie et al., 2004) with an average of 1.5kg gained one year after the end of 
treatment, 2.7kg after two years, and 2.8kg three years following completion of treatment 
(Makari-Judson et al., 2007). Though hyperinsulinemia and insulin resistance (measured by 
HOMA) have been correlated with body mass index (BMI) in breast cancer patients (Goodwin et 
al., 2009), it is important to specifically evaluate changes in fat and lean mass since weight and 
BMI measures cannot distinguish changes in particular compartments of body composition. For 
example, the loss of muscle in a patient might be masked by weight gain, and consequently, fat 
gains may be underestimated in the circumstances where muscle is lost. An increase in fat mass 
and, a concomitant decrease in lean mass, is seemingly characteristic in breast cancer patients 
and can increase the risk for developing chronic diseases in survivorship (Harvie et al., 2004; 
Mourtzakis & Bedbrook, 2009).  
Unique to breast cancer patients in comparison to non-malignant individuals is that their 
increase in fat mass is accompanied by a decrease in lean mass. This decrease in lean mass has 
been shown within 6 months of diagnosis as well as 12 months post-diagnosis (Cheney et al., 
1997; Demark-Wahnefried et al., 2001; Demark-Wahnefried et al., 2002; Freedman et al., 2004; 
Harvie et al., 2004). Opposing results, with no change in lean mass following adjuvant 
chemotherapy, was found by one group, although a sample size of only 8 breast cancer patients 
was used to come to this conclusion (Campbell et al., 2007). The majority of studies have 
investigated the effects of chemotherapy on body composition but few have looked at the effects 
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of radiation therapy. Demark-Wahnefried et al (2001), found that chemotherapy was associated 
with reduced lean mass while radiation therapy was not. In contrast, Kutynec et al (1999) found 
that radiation therapy also resulted in a decrease in lean mass, although the loss was not as 
profound as chemotherapy-treated patients (Kutynec et al., 1999). Therefore, it is generally 
agreed that chemotherapy treatment has specific effects on decreasing lean mass in breast cancer 
patients.  
 Recently diagnosed breast cancer patients showed elevated visceral adipose tissue, 
measured by computed tomography (CT) scans, in comparison to a matched reference group 
(Schapira et al., 1994). Increases in total fat mass are also evident with treatment in both pre- and 
post-menopausal women with breast cancer (Aslani et al., 1999; Campbell et al., 2007; Demark-
Wahnefried et al., 2002). Interestingly, Cheney et al (1997) showed increased visceral adiposity 
following treatment even in the absence of weight gain. When investigating changes in fat mass 
from treatment into survivorship, the gain found during treatment continued to increase 6 months 
and 1 year post-diagnosis (Demark-Wahnefried et al., 2001; Harvie et al., 2004). Similarly, 
Freedman et al found an increase in total body fat along with a decrease in fat free mass 6 
months following chemotherapy completion in absence of any significant weight change in these 
patients (Freedman et al., 2004). Additionally, a trend of increasing body fat with a decrease in 
BMI has been shown not just one year, but up to 3 years post-diagnosis (Irwin et al., 2005). This 
increase in fat mass was not related to caloric intake, menopausal status, stage of cancer or 
treatment (Irwin et al., 2005).  
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2.4 High caloric intake as a potential contributor to glucose metabolism impairments  
Since caloric intake, if greater than energy output, leads to adiposity, diet plays a crucial 
role in development of impairments in glucose metabolism. Breast cancer patients have shown a 
range of results when it comes to dietary changes during treatment. Some have found decreases 
in caloric consumption during chemotherapy (Demark-Wahnefried et al., 1997; Goodwin et al., 
1999). Others have found no difference between energy and macronutrient intake in breast 
cancer patients in the early stages of treatment in comparison to age- and BMI- matched non-
malignant as well as young healthy reference groups (Bell et al., 2013). Using 2-day dietary 
recalls and food frequency questionnaires, no differences were found in caloric intake or 
percentage of fat from total caloric intake over a one year period, in breast cancer patients 
receiving chemotherapy versus those receiving radiation therapy (Demark-Wahnefried et al., 
2001). This finding indicates that treatment type may not influence changes in dietary intake. 
Additionally, increases in fat mass seen in breast cancer patients was not related to changes in 
caloric or fat intake (since they remained the same over a one year period compared with 
baseline, which was close to diagnosis) (Demark-Wahnefried et al., 2001), suggesting that 
treatment or symptoms related to treatment (like cancer-related fatigue) may have led to these 
changes in body composition. Conversely, others have shown increased dietary consumption of 
fat following completion of chemotherapy or radiation treatment (Rockenbach et al., 2011). As 
such, data on the influence of diet in body composition and metabolic changes is inconsistent, 
and this may be related to the timeframe in which data were collected or the method used to 
obtain dietary information. 
It is important to consider the challenges in tracking nutrient intake acutely and over a 
lengthy period of time. There are many difficulties and imprecisions to this type of data 
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collection, making it difficult to discover small changes without a large sample population. Most 
large-scale studies use more crude measures of assessing dietary intake (such as 24- hour dietary 
recalls or food frequency questionnaires) due to the large cost and burden associated with more 
comprehensive methods (such as 3-or 7- day food diaries). The more comprehensive measures 
are still faced with challenges such as burden on the patient which may lead to poor 
documentation of dietary intake over 3 or 7 days. Patients may also unintentionally alter their 
diet. Additionally, patients undergoing treatment may have high variability across several 
assessments during their treatment trajectory due to treatment-induced symptoms. However, 
dietary analysis can provide supplementary information to better understand the changes in 
glucose metabolism in cancer patients.   
 
2.5 Inflammatory mediators as potential contributors to glucose metabolism impairments 
 There are two types of inflammation: acute and chronic. An acute inflammatory response 
will occur following a form of trauma to the body (Scott et al., 2004). This is a positive response, 
meant to aid in the healing process; however, chronic inflammation is usually negative. 
Cytokines, which by definition act on other cells, are secreted by a variety of cell types including 
adipose tissue (Clément et al., 2004; Xu et al., 2003). In a state of obesity, pro-inflammatory 
cytokines are often elevated, leading to issues such as insulin resistance (Xu et al., 2003). 
In non-malignant populations, chronic low-grade inflammation has been well 
documented and is correlated with glucose impairment and type 2 diabetes (Donath & Shoelson, 
2011; Temelkova-Kurktschiev et al., 2002; Xu et al., 2003). Increasing fat mass, especially 
central obesity, has been proposed to provide a hypoxic environment which leads to infiltration 
of macrophages (Donath & Shoelson, 2011; Xu et al., 2003). These macrophages then release 
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pro-inflammatory cytokines such as tumour necrosis factor-α (TNF), Interleukin (IL) -1β, IL-6 
and IL-8, ultimately aiding in the development of impairments in glucose metabolism (Donath & 
Shoelson, 2011; Xu et al., 2003).! Xu et al (2003) demonstrated that macrophage and 
inflammatory gene expression were upregulated prior to increased concentrations of circulating 
insulin; therefore suggesting that obesity-related inflammation may be a precursor to insulin 
resistance (Xu et al., 2003).  
Inflammatory mediators has been an area of interest for research in breast cancer patients 
as well. Despite that some studies have not found significant increases in pro-inflammatory 
cytokines (Bell et al., 2013; Pusztai et al., 2004), there are several studies that have conversely 
demonstrated increased inflammation in breast cancer patients, which may be associated with 
increased risk for developing impaired glucose metabolism in survivorship. Breast cancer 
patients were found to have elevated pro-inflammatory cytokine concentrations in comparison to 
a healthy female reference group, especially as cancer stage increased (stage III vs II) 
(Kozłowski et al., 2003). In line with this association between pro-inflammation and disease 
stage, tumour production of inflammatory cytokines is related to increased risk of tumour 
metastasis as well as cancer recurrence (Cole, 2009). TNFα, a pro-inflammatory marker, which 
has been shown to be elevated in breast cancer patients, is also linked to increasing tumour 
growth and proliferation as well as impaired insulin signaling at the muscle (Lee et al., 2003; 
Plomgaard et al., 2005; Rivas et al., 2008). C-reactive protein (CRP), another marker of 
inflammation, has been shown to be elevated in breast cancer patients and was associated with 
decreased survival rates in this patient population (Pierce et al., 2009).  However, not all existing 
literature has revealed increases in pro-inflammatory cytokines in breast cancer patients. Our lab 
compared a small group of Stage I-IIIa breast cancer patients (n=8) to an age- and BMI- matched 
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non-malignant female group as well as a healthy young female group found no significant 
differences in serum pro-inflammatory and anti-inflammatory cytokines between breast cancer 
patients and either reference group (Bell et al., 2013). Similar findings were found by Puszati et 
al (2004). However, given the complexity in studying cytokines and the variable, and relatively 
short half-lives that characterize many cytokines, small sample sizes may not be adequate for 
understanding the role of cytokines in glucose regulation in breast cancer. It is possible that 
inflammation may be a common, but complex, link between breast cancer, obesity, and diabetes 
in breast cancer and, may be related to different stages of the disease.  
!
2.6 The role of physical inactivity in glucose regulation 
 Physical inactivity has been associated with a number of health conditions, including at 
least 10% of breast cancer cases in the world (Lee et al., 2012). Furthermore, inactivity has been 
shown to result in 9% of premature deaths which equates to over 5.3 million individuals in 2008 
alone (Lee et al., 2012). Although physical activity is immensely important, it is a simple 
modifiable lifestyle factor that remains difficult to implement and manage in daily routines.  
One common model that has been used to study the metabolic effects of prolonged 
periods of physical inactivity is through bed rest. Oral glucose tolerance tests revealed that 5 
days of bed rest in healthy participants significantly increased the insulin and glucose responses 
(Hamburg et al., 2007). Additionally, fasting glucose and insulin concentrations were elevated as 
well (Hamburg et al., 2007), suggesting that less than a week of inactivity can adversely affect 
overall glucose handling. It is possible that impaired vascular function, which was shown in bed-
ridden participants (Hamburg et al., 2007), played a part in reducing insulin sensitivity by 
hindering delivery of glucose to the muscles for uptake. A sedentary lifestyle can be expected to 
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ultimately lead to impaired glucose metabolism. This is in line with work by Amati et al (2009), 
where chronically sedentary individuals were less insulin sensitive than regularly active 
individuals.  
 Although few studies have focused investigations on changes in physical activity post-
diagnosis , decreases in physical activity have been reported in breast cancer patients (Irwin et 
al., 2003; Irwin et al., 2004). Moderate- and vigorous- intensity, as well as sports and 
recreational activity, are significantly reduced following breast cancer diagnosis compared to 
pre-diagnosis (Irwin et al., 2003).  This decreasing time spent in an active state is associated with 
increasing categories of BMI (Irwin et al., 2004), and increasing age was also significantly 
related with decreased the time spent in vigorous-intensity physical activity (Irwin et al., 2004). 
Although decreases in physical activity were more prevalent in breast cancer patients with a 
greater BMI and age (Irwin et al., 2004), increased sedentary behavior has been found post-
breast cancer diagnosis compared with prior to diagnosis in patients with any BMI, age, stage of 
breast cancer or treatment type (Irwin et al., 2003). Total physical activity declined by the 
greatest magnitude in patients that received chemotherapy (Irwin et al., 2003). It is possible that 
this is the case due to chemotherapy related side effects such as nausea and fatigue. 
Chemotherapy-related fatigue has been reported beyond one year of treatment (Goodwin et al., 
2002). Breast cancer survivors, at least 3 years post-diagnosis, also showed increased sedentary 
behaviour in comparison to non-malignant individuals (Kim et al., 2013). It is possible that this 
is at least partially to blame for the long term increase in fat mass and decrease in lean mass; 
both of which play a role in insulin resistance. A decrease of physical activity in breast cancer 
patients has shown to lead to sarcopenic obesity (Demark-Wahnefried et al., 2001), further 
demonstrating the need for interventions that promote physical activity in these patients.    
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2.7 Effects of exercise interventions on glucose and related markers  
In non-malignant populations, a balanced diet and physical activity have shown to 
improve glucose metabolism (Eriksson et al., 1997; Schmitz et al., 2010). Individuals who 
present with insulin resistance or diabetes have demonstrated improvements in insulin and 
glucose metabolism with aerobic exercise, resistance training and a combination of the two 
exercise modalities (Cuff et al., 2003; Maiorana et al., 2002).  
In diabetic patients, aerobic exercise on a cycle ergometer has been shown to induce 
GLUT4 vesicle translocation to the plasma membrane of their skeletal muscle, ultimately 
enhancing their glucose clearance (Kennedy et al., 1999). Additionally, endurance exercise in 
older women (age 60-84 years) has been associated with decreased fat mass, increased lean mass 
in the legs and improved glucose clearance as measured by an OGTT (Evans et al., 2001). 
Significant decreases in IL-6, CRP and TNF-α have also been exhibited in obese women 
undergoing an aerobic exercise intervention (12 weeks and 6 months in duration) (Straczkowski 
et al., 2001; You et al., 2004), where decreased pro-inflammatory markers occurred 
independently of adipose tissue loss (You et al., 2004). Thus, it is plausible glucose metabolism 
may improve independently as well.  
Studies investigating resistance training in non-malignant individuals also showed 
improvements in glucose related markers. Resistance exercise in 30-50 year old women showed 
decreases in fasting glucose, insulin and IGF-1 along with decreases in percentage of body fat 
following 15 weeks of training (Schmitz et al., 2002). Additionally, one year of resistance 
training in overweight women was associated with decreased CRP concentrations (Olson et al., 
2007). Thus, if improvements in glucose metabolism and related markers are independently 
observed in both aerobic and resistance exercise modalities, then it would be anticipated that 
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improvements may be of greater magnitude if aerobic and resistance exercise training was 
combined in a given exercise program.  
 A 16 week, combined resistance and aerobic training program performed by non-
malignant women with type 2 diabetes resulted in improved glucose clearance (measured by a 
euglycemic hyperinsulinemic clamp), which was correlated with decreased subcutaneous fat and 
increased muscle cross sectional area (Cuff et al., 2003). Muscle cross-sectional area was 
measured by computed tomography scans, which also demonstrated improved density, indicating 
potential reduction in fatty infiltration in muscle (Cuff et al., 2003). These women were also 
compared to a group who underwent aerobic training alone. The combined resistance and aerobic 
exercise training group showed significant improvements in insulin sensitivity compared with 
the group that underwent aerobic training only, suggesting that a combination of aerobic and 
resistance exercise are optimal in enhancing the ability to clear glucose from the circulation 
(Cuff et al., 2003). Another group studying aerobic and resistance exercise in an 8 week circuit 
training program in diabetic patients found improvements in fasting blood glucose as well as 
body fat and physical fitness parameters (Maiorana et al., 2002), further showing the benefits of 
combined exercise. Of course there is also an opposing area of research which states that aerobic 
exercise interferes with anabolic effects normally exhibited from resistance exercise (Coffey et 
al., 2009). However, the goal of the exercise interventions in this study were to improve glucose 
metabolism; thus, while interference in anabolic processes may have occurred in this study, 
participants were still able to improve glucose parameters. 
The majority of exercise training research performed in breast cancer patients focuses 
only on aerobic exercise interventions as well as breast cancer survivors rather than patients 
actively undergoing treatment. Aerobic exercise done for 120-150 minutes per week (with 3 days 
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supervised and 2 days unsupervised per week) showed improvements in parameters of metabolic 
syndrome in breast cancer survivors as well as decreases in fasting glucose 6 months after 
starting the program (Thomas et al., 2013). While others found no changes in insulin resistance, 
insulin or glucose concentrations, however IGFBP-3 increased and IGF-1 as well as IGF-
1:IGFBP-3 molar ratio decreased following 15 weeks of aerobic training (3 times per week for 
15 to 35 minutes on a cycle ergometer) in breast cancer survivors (Fairey et al., 2003). It is 
possible that the duration of the study may have had an influence on these results. However, the 
findings regarding IGF-1 and IGFBP-3 are important because bioactive IGF-1 acts as a tumour 
proliferative and antiapoptotic agent, and aerobic exercise improved these markers in breast 
cancer survivors.  
Related measures such as body composition and inflammatory markers have been 
assessed in aerobic exercise studies done on breast cancer patients as well. A decrease in 
percentage of body fat has been observed in patients undergoing chemotherapy undertaking an 
aerobic exercise program on a cycle ergometer 3 times per week for a mean of 17 weeks in total 
(Courneya et al., 2007). Furthermore, decreases in waist circumference were demonstrated in 
breast cancer patients who adhered to the prescription of exercising 2 times per week on a 
treadmill, stationary bike or rowing ergometer (Guinan et al., 2013). Studies assessing 
inflammatory markers found that 3, 3.5 and 6 months of aerobic exercise training decreased CRP 
levels in breast cancer survivors (Fairey et al., 2005; Guinan et al., 2013; Jones et al., 2013). 
Interestingly, Guinan et al (2013) found greater decreases in CRP during the 8 week supervised 
portion of the exercise intervention. Despite decreases in CRP, the 6 month aerobic exercise 
intervention (consisting of brisk walking or, less commonly, training on a stationary bike or 
elliptical) and also reported increases in IL-6 and TNF-α (Jones et al., 2013). 
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 Research on resistance exercise in breast cancer patients is more sparse. Six months of 
partially supervised (supervised small groups by fitness professional for first 3 months) 
resistance training performed 2 times per week has shown decreases in percentage of body fat 
and increases in lean in breast cancer survivors (Schmitz et al., 2005). Other metabolic markers 
such as insulin and glucose were unchanged (Schmitz et al., 2005). In these patients, as well as 
breast cancer patients performing resistance exercise during treatment (one of the few papers that 
examined exercise training during treatment), lean body mass increased with training, and 
percentage of body fat decreased (Courneya et al., 2007; Schmitz et al., 2005), without any diet 
intervention strategies. Upper and lower body strength improved in patients performing 
resistance exercise (Courneya et al., 2007). Evidently, there are independent benefits from both 
aerobic and resistance training, and so, combining the two exercise modalities may lead to 
greater metabolic benefits.  
Even fewer studies have investigated the effects of a combination of aerobic and 
resistance exercise training on glucose metabolism in breast cancer patients. Sixteen weeks of 
combined, partially supervised (with the resistance training sessions supervised and the home-
based aerobic training portion unsupervised) exercise has shown to decrease fasting insulin as 
well as tending to decrease HOMA-IR in breast cancer survivors (Ligibel et al., 2008). 
Following the exercise intervention, no changes were reported in fasting glucose or features of 
body composition (such as fat mass or lean mass); however, waist circumference tended to 
decrease (Ligibel et al., 2008). Another study investigating measures related to glucose 
metabolism impairments used group exercise training and found that 16 weeks of aerobic and 
resistance exercise training 3 times per week improved aerobic capacity, strength and resting 
systolic blood pressure (Kolden et al., 2002). Inflammatory markers assessed in breast cancer 
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survivors showed improvements in IL-8 and CRP in a reference group completing 6 months of 
aerobic, strength and flexibility exercises (Parma et al., 2015). Conversely, results from another 
group showed unexpected increases in IL-6 and decreases in IL-10 following 3 months of 
unsupervised aerobic and resistance band exercises (Rogers et al., 2013). There is limited work 
that examines the effects of supervised, combined aerobic and resistance exercise training on 
glucose and related measures.  
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3.0 Rationale  
Breast cancer patients have been shown to develop poor glucose clearance and related 
markers with treatment and into survivorship (Bell et al., 2013; Can et al., 2013; Goodwin et al., 
2009; Guinan et al., 2013; Ligibel et al., 2008; Lu et al., 2014). Additionally, body composition 
changes of increasing fat mass and decreasing lean mass are exhibited by breast cancer patients 
following treatment (Aslani et al., 1999; Campbell et al., 2007; Cheney et al., 1997; Demark-
Wahnefried et al., 2001; Demark-Wahnefried et al., 2002; Freedman et al., 2004; Harvie et al., 
2004). This increases their risk of developing secondary diseases such as type 2 diabetes in 
survivorship (Bordeleau et al., 2011; Juanjuan et al., 2015; Lipscombe et al., 2013; Patnaik et al., 
2011; Ravasco et al., 2005). With 5-year survival rates being 88% (Canadian Cancer Society, 
2015), the proportion of survivors is escalating; thus, understanding changes in glucose 
metabolism is important to help prevent the development of diabetes in survivors. 
 
 It has been stated that exercise rehabilitation is not generally included in patient care 
(Jones & Courneya, 2002). Additionally, physical activity levels typically decrease in breast 
cancer patients (Irwin et al., 2003; Irwin et al., 2004). This is largely due to treatment-related 
fatigue, which has been reported to be present past 1 year of treatment (Goodwin et al., 2002). It 
is likely that decreased physical activity contributes to the development of impaired glucose 
metabolism and unfavourable changes in body composition in breast cancer patients, and that 
exercise training might prevent or offset these negative changes. The majority of studies 
investigating the effects of exercise in this patient population have looked at breast cancer 
survivors rather than patients undergoing treatment. Based on the deleterious changes that occur 
with treatment, it would make sense to study the effects of exercise during breast cancer 
treatment as a fo
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survivors have investigated aerobic exercise with few investigating resistance training or a 
combination of the two. Aerobic exercise and resistance training have each shown distinct 
benefits. For instance, a study directly comparing the two types of interventions in breast cancer 
patients found that aerobic exercise improved aerobic capacity and decreased percentage of body 
fat while resistance training increased muscular strength and lean mass (Courneya et al., 2007). 
A combined aerobic and resistance training program may capture a combination of these 
improvements and provide the most benefits towards improving glucose regulation.  
 
 Here, we examined the effects of a combined, supervised aerobic and resistance training 
program on glucose and related markers in breast cancer patients who were actively undergoing 
anti-neoplastic treatment. We used highly precise modalities for body composition measures. 
Fitness outcomes (strength, cardiovascular capacity, resting heart rate, and systolic and diastolic 
blood pressure) were measured and nutrition was assessed to better understand and interpret 
findings related to potential longitudinal changes in glucose and related markers. This is the first 
comprehensive and integrative examination of the effects of combined aerobic and strength 
training that has been performed, to our knowledge, in a breast cancer patients in active 
treatment. Previous literature have assess glucose metabolism, body composition, inflammatory 
markers, nutrition and fitness but never all together. Furthermore, measures such as c-peptide, 
lactate and IGF-1:IGFBP-3 are novel measures in the field of exercise and breast cancer as well.   
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4.0 Objectives  
Primary Objectives 
In a heterogeneous group of breast cancer participants, our primary objectives were to: 
1. a. Evaluate glucose and related parameters and compare these to a reference group of 
young, apparently healthy females. 
b. Compare body composition (i.e. waist circumference, lean mass and adiposity), 
inflammatory markers, aerobic capacity and strength, and dietary intake with a young, 
healthy female reference group to explain potential deviations in glucose and related 
parameters in the breast cancer participants. 
2. a. Examine potential changes in glucose and related parameters following 24 sessions of 
a combined cardiovascular and strength training program. 
b. Examine potential changes in body composition (i.e. waist circumference, lean mass, 
and adiposity), inflammatory markers, aerobic and strength assessments, and dietary 
intakes following 24 sessions of a combined cardiovascular and strength training 
program. 
 
Secondary Objectives 
In a heterogeneous group of breast cancer participants, our secondary objectives were to: 
1. a. Examine the number of sessions that participants completed. Of those who completed 
the full 24 sessions of exercise training, we will examine the time to completion of this 
program. Also, to assess whether time to completion of the 24 exercise sessions had 
potential effects on metabolic parameters. 
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b. Assess potential differences on baseline metabolic and body composition parameters 
between all participants who dropped out of the study and those that completed the 
program.  
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5.0 Hypotheses  
Primary Hypotheses 
1. Compared with the young, healthy reference group, breast cancer participants we 
hypothesized: 
a. Worse fasting glucose concentrations and related metabolic parameters. 
b. Higher waist circumference, fat mass and lower in lean mass. 
c. Higher concentrations of pro-inflammatory cytokines and lower concentration of anti-
inflammatory cytokines.  
d. Lower aerobic capacities and muscular strength. 
e. Similar caloric intake. 
2. Compared with pre-exercise assessments, breast cancer participants that have undergone 
24 exercise sessions would present with:  
a.   Maintained or improved fasting glucose and related parameters  
b.  Maintained or lowered waist circumference, fat mass and maintained or increased lean      
mass. 
c.   Maintained or lowered concentrations of pro-inflammatory cytokines and maintained 
or increased concentrations of anti-inflammatory cytokines.  
d.   Increased aerobic capacities and muscular strength. 
e.   Maintained caloric intake. 
Secondary Hypotheses 
1. a. All participants were expected to complete at least 12 sessions of exercise. 
Furthermore, participants that complete the full 24 exercise sessions were expected to 
take longer than 12 weeks to complete the program. Of those who completed the exercise 
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program, time to completion of the 24 exercise sessions was expected to affect metabolic 
parameters (i.e. those who took less time to complete the program showed greater 
improvements).  
b. Metabolic and body composition parameters at baseline would not differ between 
breast cancer participants that completed the exercise program and the group that dropped 
out.   
        
!
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6.0 Evaluation of glucose metabolism in breast cancer patients following a combined 
aerobic and resistance exercise intervention 
The work presented in this chapter will be submitted to Clinical Nutrition as: 
Milburn A G, Di Sebastiano K, Bos L, Schmidt S, Russell C, Noble M, Thayer S, Rellinger 
Smith E, Kraemer L, Dubin J, Hanning R, and Mourtzakis M. Evaluation of glucose metabolism 
in breast cancer patients following a combined aerobic and resistance exercise intervention  
 
6.1 Introduction 
Breast cancer is the most common cancer in women (Canadian Cancer Society, 2015). 
With emerging successes in detection and treatment, 5-year survival rates have reached 88%, 
thereby rapidly increasing the population of breast cancer survivors (Canadian Cancer Society, 
2015). Impairments in glucose metabolism have been found throughout the treatment trajectory 
(Bell et al., 2013; Can et al., 2013; Goodwin et al., 2009; Guinan et al., 2014), increasing the risk 
of developing secondary diseases such as diabetes in survivorship. Understanding the 
development of impaired glucose metabolism during the disease trajectory and identifying ways 
to mitigate these impairments are becoming increasingly important areas of research.  
Obesity, muscle atrophy, pro-inflammation, increased caloric intake as well as reduced 
physical activity contribute to insulin resistance in non-malignant populations (Amati et al., 
2009; Donath & Shoelson, 2011; Hamburg et al., 2007; Spiegelman & Flier, 2001). Breast 
cancer patients have demonstrated increases in fat mass and decreases in lean mass during 
treatment and into survivorship (Aslani et al., 1999; Campbell et al., 2007; Cheney et al., 1997; 
Demark-Wahnefried et al., 2001;  Demark-Wahnefried et al., 2002; Freedman et al., 2004; 
Harvie et al., 2004). Multiple studies have demonstrated increased inflammatory markers in 
breast cancer patients (Kozłowski et al., 2003; Lee et al., 2003; Pierce et al., 2009; Plomgaard et 
al., 2005; Rivas et al., 2008). Though caloric intake may not change significantly in breast cancer 
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patients undergoing treatment (Bell et al., 2013; Demark-Wahnefried et al., 2001), physical 
activity has been shown to decrease (Irwin et al., 2003); ultimately, this would lead to a positive 
net energy balance resulting in weight gain (Spiegelman & Flier, 2001). Much of this weight 
gain is likely increased adiposity masking a loss of lean tissue mass. Adiposity is a known 
contributor to impaired glucose metabolism (Amati et al., 2009). Given that skeletal muscle 
contributes  ~85% of whole body glucose disposal (DeFronzo et al., 1981), loss of lean tissue 
may also contribute to glucose dysregulation.  
Exercise interventions have been evaluated with the aim of alleviating negative side 
effects from treatment (Courneya et al., 2014; Courneya et al., 2007); however, metabolic effects 
of exercise in breast cancer patients are unclear. Few studies have investigated the effects of 
exercise on glucose metabolism, and those that have are focused only on breast cancer survivors 
(Courneya et al., 2007; Fairey et al., 2003; Guinan et al., 2013; Segal et al., 2001; Thomas et al., 
2013). Despite the profound improvements in glucose disposal that result from combined aerobic 
and resistance exercise in non-malignant populations (Cuff et al., 2003), few studies in breast 
cancer survivors and no studies in breast cancer patients undergoing treatment have used this 
approach to improve metabolic outcomes. In breast cancer survivors, Ligibel et al. (2008) 
showed improvements in fasting insulin following a 16 week combined aerobic and resistance 
training program (Ligibel et al., 2008). Another study used group exercise training and found 
that 16 weeks of aerobic and resistance exercise training 3 times per week improved aerobic 
capacity, strength and resting systolic blood pressure (Kolden et al., 2002).  
The aim of this study was to investigate the effects of a 24-session, mixed aerobic and 
resistance exercise program on glucose metabolism. Body composition, diet and inflammatory 
markers were measured to support our understanding of the potential changes in glucose-related 
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parameters during the exercise program. Baseline and post-training measures were additionally 
compared to a group of young, healthy females. We hypothesized that breast cancer patients 
would demonstrate improvements in all glucose-related parameters, and these changes may be 
related to reduced body fat, pro-inflammatory mediators and increased lean mass.    
 
6.2 Methods  
6.2.1. General study design 
This study involved 25 participants: 15 female breast cancer patients (>18 years old) and 
10 healthy, young females (18-25 years old with normal fasting blood glucose). Following 
medical clearance, all participants were assessed for: 1) fitness (including cardiovascular and 
muscular strength), 2) glucose-related measures and inflammatory markers from fasted blood 
sample, 3) body composition using body mass index (BMI), dual energy X-ray absorptiometry 
(DXA), and waist circumference (WC), and 4) dietary intake using 3-day food diaries. All of 
these baseline assessments were completed within 1 week and compared with a young, healthy 
reference group. Following the baseline assessment, breast cancer participants underwent a 24-
session exercise intervention including a combination of strength and aerobic training. The 
assessments performed at baseline were then repeated at cessation of the exercise program for 
longitudinal comparisons. This study was reviewed and received ethics clearance by the 
University of Waterloo Office of Research Ethics Board for both the breast cancer and young 
healthy female participants and by the Tri-Hospital Research Ethics Board for the breast cancer 
participants. 
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6.2.2 Participants 
Breast cancer patients and survivors (survivors being participants that have recently 
finished treatment) were recruited who: were physically able to exercise, were at any stage of the 
disease, received any treatment, and were at any stage of treatment (even if recently completed). 
Patients were referred by oncologists from a local community cancer centre to participate in 
exercise training at the University of Waterloo WELL-FIT Centre.  
The young, healthy female reference group was recruited from the Kitchener-Waterloo 
region and included recreationally active women who had fasting blood glucose concentrations 
<5.6mM and who did not have any adverse medical conditions or history of medical conditions. 
Participants completed all tests within day 1-7 of their menstrual cycle.  
6.2.3 Blood sampling and biochemical analysis 
Participants arrived in the morning, following an 8-hour overnight fast. A sterile catheter 
was inserted into an antecubital vein for the collection of 40mL of blood. Less than 1mL of 
whole blood was used to measure glycated albumin (HbA1c) (using A1c now+, Bayer, 
Mississauga, ON) as well as fasting blood glucose (using accu-check aviva glucose meter, Roche 
Diagnostics, Mississauga, ON). Remaining blood was allowed to clot for 30 minutes at room 
temperature before being centrifuged. Serum was stored at -80°C and used to assess glucose, 
insulin, c-peptide, IGF-1, IGFBP-3, lactate, TNF-α, IL-6, IL-4, IL-8, IL-10, and CRP.  
 Radioimmunoassays were used to measure insulin (Insulin Specific Radioimmunoassay 
kit, Millipore; Etobicoke, ON), and c-peptide (Human C-Peptide Radioimmunoassay kit, 
Millipore; Etobicoke, ON). ELISA kits were used to measure IGF-1 (Human IGF-1 Quantikine 
ELISA kit, R&D Systems; Minneapolis, MN), and IGFBP-3 (IGFBP-3 Quantikine ELISA kit, 
R&D Systems; Minneapolis, MN). Lactate was measured by spectrofluorophotometric assay 
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(method modified from Marbach & Weil, 1967). Inflammatory mediators, TNF- α, IL-6, IL-8, 
IL-10 and IL-4 were measured using a BD Biosciences FACSCalibur flow cytometer and the BD 
Cytometric Bead Array (Human Soluble Protein Master Buffer Kit, BD Bio- sciences; 
Mississauga, ON). Lastly, ELISA kits were used to measure CRP (Human C-Reactive 
Protein/CRP Quantikine ELISA kit, R&D Systems; Minneapolis, MN).  
6.2.4 Body Composition 
Body composition measures including DXA, BMI and WC were performed for all 
healthy reference participants and at baseline and post-training in the breast cancer patients. 
Using DXA (Hologic Discovery, Hologic, Toronto, ON), fat mass and lean mass for the whole 
body and for specific regions of the body were evaluated for the identification of sarcopenic 
individuals. Sarcopenic individuals were categorized by using the cut off of < 5.45 kg/m2 of 
appendicular lean mass (Baumgartner et al., 1998). BMI (kg/m2) was assessed using their weight 
(kg) and height (m). WC, which is a criteria for assessing metabolic syndrome (if >88cm) 
(Alberti et al, 2006), was measured at the top of the iliac crests (American College of Sports 
Medicine, 2009) with a cotton measuring tape. DXA, BMI and WC measures were also 
performed in the young, healthy reference group but only at one time point.  
6.2.5 Nutrition Analysis 
Quality and quantity of nutrients were analyzed using 3-day food diaries. Participants 
recorded everything they ate and drank for two week days and one weekend day as previously 
described (Thompson & Byers, 1994). ESHA food processor software (ESHA research, Salem, 
OR) was used to measure daily caloric intake and macronutrient breakdown.  
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6.2.6 Cardiovascular and muscular strength assessments 
Breast cancer participants underwent a graded exercise test on a cycle ergometer. The test 
was stopped when 50rpm could no longer be maintained for a minimum of 30 seconds or a Rate 
of Perceived Exertion (RPE; using the Borg Scale) of 15 was reached. The reference group 
underwent a similar test on a cycle ergometer (ergoselect 100, ergoline; Bitz, Germany) but were 
brought to their VO2 peak utilizing a Vmax breath-by-breath system (Care Fusion; SanDiego, 
CA). The test was stopped when 50rpm could no longer be maintained for a minimum of 30 
seconds. Heart rate and blood pressure and RPE were assessed for both groups throughout the 
test (every minute for HR and every 2 minutes for BP and RPE).  
A predictive one repetition maximum (1RM) test was performed to measure muscular 
strength in the upper and lower limbs. Maximal isometric force was measured by a force 
transducer in forearm flexion as well as leg extension; contralateral sides were tested 
independently. Isometric contractions were held for 2 seconds and repeated 3 times for each test.  
6.2.7 Exercise training program 
Combined moderate cardiovascular exercise and resistance training was designed with 
prescribed heart rate range of 40-60% Heart Rate Reserve. Target heart rate was prescribed 
based on the heart rate achieved during 11-13 RPE of the cardiovascular test from the baseline 
fitness assessment. Heart rate bands (Polar; Lachine, QC) were worn for the full duration of each 
session of exercise. Resistance exercise was performed for all major muscle groups of the body. 
Participants were instructed to perform 10-20 repetitions for each exercise and progressed by 
increasing intensity to the next weight when 20 repetitions were reached at least two times with 
proper form for the entire 20 repetitions. It was the aim of the study to complete 24 sessions 
within 12 weeks (i.e. exercise 2 times per week for approximately one hour per session). Number 
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of exercise sessions completed as well as the time to complete all 24 sessions was recorded and 
assessed. All research participants were supervised during each exercise session.  
6.2.8 Calculations  
 Insulin resistance was evaluated by HOMA-IR (Bonora et al., 2000):  
 
HOMA-IR = (fasting glucose x fasting insulin)/22.5  
 
To identify participants with sarcopenia (less than normal muscularity; with values <5.45kg/m2), 
sarcopenic index was calculated using (Baumgartner et al., 1998):  
 
sarcopenic index= sum of appendicular lean mass (kg)/height2 (m2)  
 
1RM prediction was calculated by: 
 
 1RM (Nm) = moment arm (m) x highest force trial (N)  
 
BMI was measured by: 
 
BMI (kg/m2) = weight (kg)/ height (m2).  
 
6.2.9 Statistics 
Results are presented as mean ± standard deviation. Significance was reported as a p 
<0.05 and a trend was defined as 0.05 < p < 0.10. All statistical analyses were performed on 
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SigmaPlot Version 11.0 (Systat Software Inc., San Jose, CA). Independent-samples t-tests were 
used to compare baseline blood parameters and body composition measures of breast cancer 
exercise completers with the young, healthy female reference group. Paired t-tests were used to 
compare baseline parameters of the breast cancer group with the measures at cessation of the 
exercise program. Independent t-tests were used to compare the breast cancer dropouts to the 
breast cancer exercise completers to show no bias in the group of participants that completed the 
program. Linear regression analysis was used to determine whether time to completion as well as 
days since treatment initiation had an effect on changes seen in measured parameters.  
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6.3 Results 
6.3.1 Participant Characteristics 
 Out of 105 breast cancer patients referred to the University of Waterloo WELL-FIT 
program, 96 breast cancer patients started the WELL-FIT program, 36 were interested in 
participating in this study and 22 breast cancer patients consented to participation in the study 
and completed all baseline assessments including the blood draw. A final sample of 15 
participants completed the post assessment with the blood draw following completion of the 
exercise program (Figure 6.1). 
The breast cancer patient group (n=15) ranged from 34-75 years old (55± 11 years old; 
Table 6.1). Treatment consisted of a combination of surgery, chemotherapy, radiation and 
hormonal treatments, and ranged early to late treatment with one of the dropouts having recently 
completed treatment (Table 6.1).  
Overall, breast cancer participants had an average BMI in the overweight category (26.2 
± 4.0   kg/m2, n=15; Table 6.2). There were 9 participants (60%) that were overweight or obese, 
while none were underweight. In the reference group, the average BMI was in the normal range 
(23.3 ± 1.9 kg/m2; Table 6.2). Average resting heart rate, systolic and diastolic blood pressure 
were normal for the breast cancer patients as well as the young reference group (Table 6.2). 
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Figure 6.1 Breast cancer patient flow numbers. This consort diagram explains patient 
recruitment, enrollment, follow-up (explaining participants that dropped out) and the final 
sample analyzed.  
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Table 6.1 Treatment characteristics of all breast cancer participants at baseline  
Type of treatments 
undergone 
Baseline of breast 
cancer dropouts 
(n=7) 
Baseline of breast 
cancer exercise 
completers 
(n=15) 
P-values 
Chemotherapy  4 12  
Chemotherapy Stage: 
1 cycle  
2 cycles  
3 cycles  
>3 cycles  
 
1 
1 
 
2 
 
2 
3 
1 
6 
 
Days since 
chemotherapy initiation 
(mean days + SD) 
83 ± 79 85 ± 66 0.966 
Radiation  3 5  
Days since radiation 
treatment initiation 
(mean days + SD) 
22 ± 22 25 ± 16 0.835 
Recently completed 
radiation treatment with 
no treatment to follow  
1 0  
Hormone Treatment  2 6  
Days since hormone 
treatment initiation 
(mean days + SD) 
201 ± 204 54 ± 49 0.286 
 
Types of surgery 
undergone 
   
Mastectomy  3 8  
Lumpectomy  2 6  
 
All values in the table represent n-values unless otherwise stated. 
* Indicates p<0.05 
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Table 6.2 Physical characteristics of all participants 
 Baseline of 
breast cancer 
dropouts 
 
Baseline of 
breast cancer 
exercise 
completers 
 
Post-assessment 
of breast cancer 
exercise 
completers 
Young, Healthy 
Females 
Sample size  7 15 15 10 
Age 52 ± 11  54 ± 12 53 ± 11 23 ± 2 
BMI (kg/m2) 
Normal (n) 
Overweight (n) 
Obese (n) 
27.0 ± 5.3  
3 
2 
2 
26.2 ± 4.0  † 
6 
7 
2 
26.4 ± 4.2 
5 
7 
3 
23.3 ± 1.9 
7 
3 
0 
Waist 
circumference 
(cm)  
93.4 ± 13.7 
>88cm: 5 
(~71%) 
93.5 ± 13.3  † 
>88cm: 8 
(~53%) 
92.4 ± 13.5 
>88cm: 9 
(~60%) 
72.6 ± 5.0 
>88cm: 0 (0%) 
Weight (kg) 72.1 ± 11.9 70.1 ± 11.2 70.8 ± 12.2 65.6 ± 8.0 
Height (m) 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.7 ± 0.1 
Resting Heart 
Rate (bpm)  
70 ± 12  72 ± 11  † 71 ± 10 84 ± 13 
Resting Systolic 
Blood Pressure 
(mmHg) 
117 ± 16 119 ± 12 * 113 ± 10 114 ± 5 
Resting Diastolic 
Blood Pressure 
(mmHg) 
74 ± 11 78 ± 11 # 73 ± 6 77 ± 5 
 
* indicates significant differences between the baseline and post-assessment of breast cancer exercise 
completers  
# indicates a trend between the baseline and post-assessment of breast cancer exercise completers 
† indicates significant differences between baseline of breast cancer exercise completers and the young 
healthy reference group 
‡ indicates a trend between baseline of breast cancer exercise completers and the young healthy reference 
group 
Note: no statistical differences were seen between the breast cancer dropout group and the breast cancer 
exercise completers at baseline. 
BMI ranges: Normal= 18.5-24.9, Overweight= 25-29.9, Obese > 30 kg/m2 (World Health Organization, 
2000) 
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6.3.2. Glucose and related markers in breast cancer participants exercise completers at 
baseline compared to young, healthy females 
 Fasting blood samples revealed that HbA1c levels and plasma glucose were significantly 
higher in breast cancer participants than in the reference group (HbA1c= 5.8 vs 5.0 %, p< 0.001; 
plasma glucose= 5.3 vs 4.6 mM, p= 0.001;Table 6.3 and Figure 6.2, respectively). Fasting 
insulin was significantly higher and c-peptide tended to be higher in breast cancer participants 
compared with the reference group (Table 6.3). HOMA-IR was significantly higher in breast 
cancer patients as well (Figure 6.3). Insulin-like growth factor (IGF) -1 as well as concentrations 
of IGF binding protein- 3 (IGFBP-3) were lower in breast cancer participants versus young 
healthy females (Table 6.3). However, the ratio of IGF-1:IGFBP-3 were not different between 
groups (Table 6.3).  
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Figure 6.2 Fasting plasma blood glucose concentrations in breast cancer participants pre- 
and post- exercise program in comparison to young, healthy females. International Diabetes 
Federation (IDF) cut-point (represented as the dashed line) indicates fasting glucose 
concentrations above 5.6mM to be a risk factor for metabolic syndrome (IDF, 2006). Pre-
exercise values were higher than the reference group but decreased post-exercise intervention. 4 
participants were above the IDF cut-point at baseline and only 1 was above post-exercise 
program. 
Legend: 
 
* Indicates p<0.05 
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Figure 6.3 HOMA-IR results in breast cancer participants pre- and post- exercise program 
in comparison to young, healthy females. HOMA-IR was higher at pre-exercise than the 
reference group but tended to decrease post-exercise program. 
Legend: 
 
* Indicates p<0.05 
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Table 6.3 Glucose related markers in breast cancer participants and in young, healthy 
females  
 Baseline of 
breast 
cancer 
dropouts 
(n=7) 
Baseline of 
breast cancer 
exercise 
completers 
(n=15) 
Post-assessment 
of breast cancer 
exercise 
completers 
(n=15) 
Young, 
Healthy 
Females 
(n=10) 
HbA1c (%) 
Range 5.7-6.41 (n) 
Range 6.0-6.42 (n) 
> 6.52 (n) 
6.2 ± 1.5 
4 
2 
1 
5.8 ± 0.7 † 
6 
2 
2 
- 5.0 ±  0.4 
1 
0 
0 
Insulin  (µlU/mL) 19.7 ± 7.0 18.3 ± 6.1 † 16.2 ± 6.4 13.2 ± 4.7 
C-peptide  (ng/ml) 6.5 ± 2.3 5.3 ± 2.3 ‡ 4.9 ± 2.9 3.7 ± 1.1 
IGF-1 (ng/mL) 133.2 ± 
54.4  
108.9 ± 45.2 † # 87.3 ± 26.9 † 168.2 ± 41.1 
IGFBP-3 (ng/mL) 355.7 ± 
66.2 
331.4 ± 81.1 † 340.1 ± 77.7† 453.7 ± 65.9 
IGF-1:IGFBP-3 0.38 ± 0.13  0.33 ± 0.11 * 0.27 ± 0.09 0.37 ± 0.09 
Lactate (mM) 2.5 ± 0.8  2.9 ± 1.3 # 2.2 ± 0.7 2.3 ± 0.7 
 
* indicates significant differences between the baseline and post-assessment of breast cancer exercise 
completers  
# indicates a trend between the baseline and post-assessment of breast cancer exercise completers 
† indicates significant differences between baseline of breast cancer exercise completers and the young 
healthy reference group 
‡ indicates a trend between baseline of breast cancer exercise completers and the young healthy reference 
group 
Note: no statistical differences were seen between the breast cancer dropout group and the breast cancer 
exercise completers at baseline. 
1  (American Diabetes Association, 2015) 
2  (Canadian Diabetes Association, 2013) 
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6.3.3 Comparison of body composition, inflammatory markers, physical fitness, and dietary 
intake between breast cancer participants and young, healthy females  
WC was also significantly higher for breast cancer participants than the reference group 
(94 vs 73 cm, p< 0.001; Table 6.2). There were 8 of 15 breast cancer participants that were 
abdominally obese (defined as WC >88cm). In line with this finding, body fat % measured by 
DXA was significantly higher for breast cancer participants than the reference group (38.2 vs 
31.2 %, p= 0.002;Table 6.4). Total lean mass in the limbs was significantly lower in the breast 
cancer participants compared with the reference group (Table 6.4). Interestingly, 5 breast cancer 
participants and none of the reference group were sarcopenic (<5.45 kg/m2). 
 Pro-inflammatory mediators (TNF- α, IL-6, IL-8, IL-1β and CRP) and anti-inflammatory 
cytokines (IL-4 and IL-10) showed no significant differences between the breast cancer 
participants and the young healthy female reference group (Table 6.5). Predicted VO2peak was 
lower in breast cancer participants as compared with VO2peak measured in the young female 
reference group (29.0 vs 42.0 mL/kg/min, p= 0.008; Table 6.4). Additionally, muscular strength 
of all four limbs was lower in the breast cancer group (Table 6.4).  
 Total caloric intake was significantly lower in the breast cancer participants than the 
young healthy reference group (1886 ± 328 vs 2262 ± 578 kcal, p=0.008). When investigating 
percentage of macronutrient intake, no differences were seen between the two groups (Appendix 
IV).   
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Table 6.4 Body composition & fitness measures in breast cancer participants and in young, 
healthy females 
 Baseline of 
breast cancer 
dropouts 
(n=7) 
Baseline of 
breast cancer 
exercise 
completers 
(n=14) 
Post-
assessment of 
breast cancer 
exercise 
completers 
(n=14) 
Young, 
Healthy 
Females 
(n=10)  
Body Composition 
% body fat  39.9 ± 5.9 38.2 ± 5.3 †* 39.9 ± 5.0 31.2 ± 3.8 
Total fat mass (kg) 28.6 ± 8.4 25.8 ± 6.0 †* 27.3 ± 7.3 20.3 ± 4.5 
Total lean mass 
(kg)  
39.6 ± 4.2  39.2 ± 6.2  38.3 ± 5.3 41.8 ± 3.8 
Total lean mass in 
the limbs (kg) 
16.8 ± 1.9 16.3 ± 3.0 16.2 ± 2.6 18.4 ± 1.8 
Appendicular 
Skeletal Muscle 
Mass (kg/m2) 
6.3 ± 0.8 6.1 ± 0.9 6.00 ± 0.7 6.6 ± 0.5 
Fitness Measures 
Isometric Right 
Arm Flexion (Nm) 
34.7 ± 5.7 30.2 ± 10.9 † 32.5 ± 11.5 41.3 ± 10.5 
Isometric Left 
Arm Flexion (Nm) 
29.2 ± 8.3 28.2 ± 10.2 † 
(n=13) 
30.4 ± 10.6 
(n=13) 
41.9 ± 12.8 
Isometric Right & 
Left Arm Flexion 
(Nm) 
63.9 ± 10.6 56.9 ± 19.6 † 
(n=13) 
61.4 ± 20.5 
(n=13) 
83.2 ± 23.1 
Isometric Right 
Leg Extension 
(Nm) 
99.3 ± 27.1 88.8 ± 28.5 †# 96.0 ± 33.5 168.4 ± 28.9 
Isometric Left Leg 
Extension (Nm) 
101.6 ± 22.1 84.1 ± 30.1 †* 98.7 ± 33.4 166.9 ± 30.0 
Isometric Right & 
Left Leg 
Extension (Nm) 
200.9 ± 47.7 172.9 ± 56.3 †* 194.8 ± 66.3 335.3 ± 57.2 
VO2 peak 
(mL/kg/min) 
32.7 ± 7.8 29.0 ± 8.6 †*  
(n=13)  
31.3 ± 9.4 
(n=13) 
42.0 ± 2.7 
 
* indicates significant differences between the baseline and post-assessment of breast cancer exercise 
completers  
# indicates a trend between the baseline and post-assessment of breast cancer exercise completers 
† indicates significant differences between baseline of breast cancer exercise completers and the young 
healthy reference group 
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‡ indicates a trend between baseline of breast cancer exercise completers and the young healthy reference 
group 
Note 1: no statistical differences were seen between the breast cancer dropout group and the breast cancer 
exercise completers at baseline. 
Note 2: n=14 resulted due to scheduling difficulties for either baseline DXA scan or fitness post-
assessment.  
Note 3: n=13 because a participant was restricted to using only her right arm or because there was an 
outlier (defined as more than 2 SD from the mean) in the VO2 peak data.   
 
  
! 48!
Table 6.5 Concentrations of inflammatory mediators in breast cancer participants and in 
young, healthy females  
 Baseline of 
breast cancer 
dropouts 
 
Baseline of 
breast cancer 
exercise 
completers 
Post-assessment 
of breast cancer 
exercise 
completers 
Young, Healthy 
Females 
Pro-inflammatory cytokines 
TNF-α 
(pg/mL) 
6.7 ± 0.7 (n=6) 5.9 ± 0.7 * (n=7) 7.2 ± 1.2 (n=7) 6.7 ±1.2 (n=7) 
IL-6 (pg/mL) 7.6 ± 1.7 (n=4) 6.7 ± 2.5 (n=7) 8.4 ± 4.8 (n=7) 5.4 ± 0.4 (n=4) 
IL-8 (pg/mL) 14.8 ± 2.7 (n=6) 12.4 ± 3.4 
(n=13) 
14.5 ± 4.4 
(n=13) 
13.5 ± 5.1 
(n=10) 
IL-1β 
(pg/mL) 
6.5 ± 0.3 (n=4) 6.0 ± 0.6 # (n=8) 6.9 ± 1.2 (n=8) 6.4 ± 0.8 (n=7) 
CRP (mg/L) 0.2 ± 0.1 (n=15) 0.3 ± 0.2 (n=15) 0.3 ± 0.2 (n=15) 0.2 ± 0.1 (n=15) 
Anti-inflammatory cytokines 
IL-4 (pg/mL) 5.2 ± 0.2 (n=3) 6.0 ± 0.7 (n=7) 6.5 ± 1.0 (n=7) 5.9 ± 0.6 (n=3) 
IL-10 
(pg/mL) 
6.2 ± 0.7 (n=7) 6.5 ± 1.6 (n=13) 6.4 ± 1.1 (n=13) 6.4 ± 1.3 (n=10) 
 
* indicates significant differences between the baseline and post-assessment of breast cancer exercise 
completers  
# indicates a trend between the baseline and post-assessment of breast cancer exercise completers 
† indicates significant differences between baseline of breast cancer exercise completers and the young 
healthy reference group 
‡ indicates a trend between baseline of breast cancer exercise completers and the young healthy reference 
group 
Note 1: no statistical differences were seen between the breast cancer dropout group and the breast cancer 
exercise completers at baseline. 
Note 2: n values vary based on detection rates of cytokine analysis.  
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6.3.4. Effect of 24 exercise sessions on glucose and related markers in breast cancer 
participants (n=15) 
 Following the exercise program, breast cancer participants presented with fasting plasma 
glucose lower than baseline (5.4 ± 0.7 vs. 5.0 ± 0.4 mM, p=0.008; Figure 6.2). Fasting insulin 
and c-peptide concentrations did not change significantly following the exercise program (Table 
6.3). HOMA-IR scores tended to improve with exercise (4.4 ± 1.6 vs. 3.6 ± 1.7, p= 0.062; Table 
6.3). IGF-1 concentrations tended to decrease in participants that completed the exercise program 
(108.9 ± 45.2 vs 87.3 ± 26.9 ng/mL, p= 0.061; Table 6.3). IGF-1:IGFBP-3 ratio significantly 
improved (0.33 ± 0.12 ng/mL vs 0.27 ± 0.09, p= 0.018; Table 6.3), despite the lack of change in 
IGFBP-3 (Table 6.3). Lactate concentrations tended to decrease following the exercise program 
(Table 6.3).  
 
6.3.5 Comparison of body composition, inflammatory markers, physical fitness, and dietary 
intake between pre- and post-exercise training in breast cancer participants  
Weight, BMI, and WC did not change with exercise training (Table 6.2). Surprisingly, 
body fat % increased following exercise program (38.2 ± 5.3 vs. 39.9 ± 5.0%, p= 0.038; Table 
6.4). Total fat mass also showed significant increases (25.8 ± 6.0 vs. 27.3 ± 7.3 kg, p= 0.038; 
Table 6.4). Total lean mass as well as total appendicular lean mass did not change (Table 6.4). 
Appendicular skeletal muscle mass index (normalized by height) also remained similar after the 
exercise program (6.0 ± 0.9 vs 5.9 ± 0.8 kg/m2, p= 0.182; Table 6.4). Interestingly, only 3 
participants were in the sarcopenic range following the program compared with 5 sarcopenic 
participants at baseline.  
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 Pro-inflammatory cytokine TNF- α increased significantly post-exercise intervention (5.9 
± 0.7 vs 7.2 ± 1.2 pg/mL, p=0.011; Table 6.5) and IL-1β tended to increase (6.0 ± 0.6 vs 6.9 ± 
1.2 pg/mL, p=0.095; Table 6.5). Delta TNF-α  (which showed increases from baseline to post-
exercise program) was correlated with increasing delta of percentage of fat  (r= 0.873, p=0.0230) 
and total fat mass (r= 0.908, p=0.0124, n= 6). Pro-inflammatory cyotkines IL-6, IL-8 and CRP as 
well as anti-inflammatory cytokines, IL-4 and IL-10, remained unchanged with exercise training 
(Table 6.5). 
 Predicted VO2peak in breast cancer participants significantly increased following the 
exercise program (29.0 ± 8.6 vs 31.3 ± 9.4 mL/kg/min, p= 0.026; Table 6.4). Additionally, 
systolic blood pressure significantly decreased and diastolic blood pressure tended to decrease 
following the exercise program (Table 6.2). While isometric right leg extension strength only 
tended to improve with the exercise program, left isometric leg extension as well as combined 
right and left isometric leg extension strength increased following completion of the exercise 
program (Table 6.4).  
Total caloric intake remained the same between baseline and cessation of the exercise 
program (1718 ± 358 kcal vs 1729 ± 410 kcal, p=0.881). Percentage of macronutrient intake 
revealed that there were no changes in protein, carbohydrate nor fat intake (Appendix IV). No 
differences in any of the blood, body composition, inflammatory, fitness or dietary measures 
were found between the breast cancer dropout group and the breast cancer exercise program 
completers.  
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6.3.6 Time until program completion and its effects on metabolic parameters 
 Participants took an average of 132 ± 45 days (range: 84 to 218 days) to complete the 
exercise program (defined as completion of 23-24 sessions).  One participant only completed 23 
sessions prior to her post-assessment because her surgery date interfered with the scheduled 24th 
session. Interestingly, 21 of the 22 participants who had initially enrolled in the study, were able 
to adhere to the program until approximately the 12th session (Figure 6.4). Days until program 
completion was correlated with change in fasting plasma glucose measures. Reductions in 
plasma glucose were greater when the program duration was shorter (r2= 0.357, p=0.019), 
suggesting that those who followed the exercise prescription exhibited the greatest benefits in 
blood glucose. Similarly, delta TNF-α tended to increase for those that took longer to complete 
the exercise program (r2= 0.523, p=0.066). 
 
 
   
 !
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Figure 6.4 Number of exercise sessions completed by participants 
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6.4 Discussion  
This is the first study, to our knowledge, that examined changes in glucose and related 
parameters following 24 sessions of supervised, combined aerobic and resistance exercise 
intervention in breast cancer patients who were concurrently receiving treatment. Compared with 
a healthy, young female reference group, breast cancer patients presented with higher fasting 
plasma glucose, HbA1c, insulin, c-peptide, HOMA-IR and lower IGF-1, and IGFBP-3. These 
differences are potentially attributed to a body composition phenotype that is higher in fat and 
lower in lean mass, greater overall age as well as lower fitness levels in the breast cancer 
patients. In contrast, dietary intake and inflammatory markers were relatively similar between the 
2 groups. We have previously shown that in a small group of BMI- and age-matched non-
malignant women, Stage I-II breast cancer patients tended to have poorer glucose handling than 
the matched reference group (Bell et al., 2013). Here, breast cancer patients that completed the 
exercise program showed significant improvements in fasting plasma glucose and IGF-1:IGFBP-
3 as well as a tendency towards improved HOMA-IR, IGF-1 and lactate concentrations. The 
exercise program led to improved physical strength and aerobic capacity suggesting that the 
integrity and metabolic function of the muscle was improved and these metabolic improvements 
may have explained the reduced plasma glucose concentrations following exercise. Lean mass, 
most inflammatory markers and dietary intake remained similar to baseline, but improvements in 
fasting glucose were associated with reduced time to complete 24 sessions of combined aerobic 
and resistance exercise training. In contrast, fat mass and TNF-α were higher than baseline 
measurements, and changes in these features were related to each other. In other words, those 
who gained fat, were likely to exhibit increases in TNF-α.  
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 In the present study, we demonstrated that 24 sessions of combined moderate intensity 
aerobic and resistance exercise was associated with improved fasting plasma glucose. The 
supervised exercise program was prescribed with a frequency of 2 times per week, however, only 
8 out of 15 participants of participants were able to complete 23-24 sessions in the prescribed 12 
week range given that factors related to the disease, treatment, family etc. may prohibit 
adherence to the prescribed frequency.  Although it took an average of ~ 132 days to complete 
the exercise program, fasting plasma glucose significantly decreased. A study investigating a 
program of supervised resistance training and unsupervised aerobic training in breast cancer 
survivors reported no significant changes in fasting blood glucose (Ligibel et al., 2008). In a 
previous study from our lab, no significant differences in fasting blood glucose were found 
between breast cancer patients and a reference group of young healthy females as well as another 
reference group of age and BMI matched females (Bell et al., 2013); only an oral glucose 
tolerance test (OGTT) was sensitive enough to depict impaired glucose clearance in the breast 
cancer group (Bell et al., 2013). Clearly, these reductions in fasting blood glucose are impressive 
but need to be interpreted with some caution as treatment itself may, independently (Guinan et 
al., 2014) or in conjunction with exercise, have contributed to this reduction. 
Previous studies on non-malignant individuals have shown increased GLUT4 protein 
content in individuals undergoing a resistance training program (Holten et al., 2004) as well as 
an aerobic training program (Hughes et al., 1993). Despite the low volume of exercise in this 
pool of participants, we predict that GLUT4 content was increased in our participants and that 
this allowed for greater clearance of plasma glucose during exercise sessions. During basal 
states, however, GLUT1 would have been responsible for glucose clearance (Kennedy et al., 
1999). Although muscle biopsies were not taken to confirm whether increased GLUT proteins or 
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GLUT translocation played a role in decreased fasting glucose, the finding of unchanged 
concentrations of circulating insulin and c-peptide imply that increased glucose clearance was 
not due to insulin-stimulated uptake. Blood draws were conducted at a minimum of 48 hours 
after exercise to ensure any acute effects of exercise were negligible. In basal conditions where 
insulin or exercise stimulated glucose uptake is not at play, it is possible that the liver has also 
decreased insulin resistance, with proper glycogen synthesis in the postprandial state and 
gluconeogenesis in the fasted state (Savage et al., 2007). Although the exercise program may 
have improved fasting plasma glucose, it is also possible that treatment could have lowered its 
concentrations as well. Literature in pancreatic cancer patients has demonstrated the ability of the 
tumour to induce insulin resistance (Permert et al., 1993; Saruc et al., 2009). It is possible that 
treatment, by eliminating the tumour and its potentially lingering effects, may have improved 
fasting glucose concentrations. However, literature in breast cancer patients has shown increases 
in glucose, insulin and c-peptide (Guinan et al., 2014; Ligibel et al., 2008) supporting the 
effectiveness of the exercise program seeing as glucose concentrations improved and insulin and 
c-peptide remained unchanged.     
 IGF-1:IGFBP-3 showed significant decreases in a group of breast cancer survivors 
undergoing an aerobic exercise training regime for 15 weeks (Fairey et al., 2003). To our 
knowledge, our study is the first to show a decrease in IGF-1:IGFBP-3 in a group of breast 
cancer patients primarily still undergoing treatment or recently completed treatment following a 
combined aerobic and resistance training program. IGF-1 resembles the molecular structure of 
insulin and has also been shown to be related to insulin resistance (Friedrich et al., 2012). The 
decreased bioavailability of IGF-1 implicated by a lower molar ratio of IGF-1:IGFBP-3 indicate 
positive effects on insulin sensitivity.  
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Although we expected muscular strength to improve significantly in the upper and lower 
body as in the study by Kolden et al (2002), we only saw improvements in the lower body. The 
improvements that were observed in strength and metabolic parameters, including fasting 
glucose, were nonetheless impressive given that the exercise protocol was based on moderate 
intensity and low frequency exercise. Additionally, an increase in aerobic capacity may have 
some implications for improved concentrations of glucose and related markers since higher 
insulin sensitivity is exhibited by aerobically active individuals (Amati et al., 2009). A number of 
measures, including body composition, which is normally related to metabolic outcomes, did not 
improve. However, breast cancer patients and survivors typically experience increasing fat mass 
and decreasing lean mass during the disease and survivorship trajectory (Aslani et al., 1999; 
Campbell et al., 2007; Cheney et al., 1997; Demark-Wahnefried et al., 2001; Demark-
Wahnefried, et al., 2002; Freedman et al., 2004; Harvie et al., 2004). However, if we had 
included a usual care group that did not undergo the exercise program, we may have found 
significant differences between the usual care and exercise intervention group with attenuated 
increases in fat mass and attenuated decreases in lean mass in the exercise intervention group.  
Based on previous studies (Bell et al., 2013; Demark-Wahnefried et al., 2001), we did not 
expect to find caloric changes as well as macronutrient intake. However, it is possible that 
participants did not expend enough energy during the exercise program to counter-balance their 
energy intakes, and this may have led to increased fat mass. Although the majority of pro- and 
anti-inflammatory mediators (CRP, IL-6, IL-8, IL-4 and IL-10) remained the same, pro-
inflammatory TNF-α increased significantly and IL-1β tended to increase following the exercise 
intervention. However, increased TNF-α may be explained by its positive correlation with the 
increase in fat mass demonstrated in this study. This relationship is supported by previous 
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literature that reported TNF-α release by macrophages in adipose tissue (Suganami & Ogawa, 
2010). Of course, cytokines such as TNF-α are released by several tissues, and may therefore 
have increased independently of increases in fat mass.  
In summary, this is the first study to assess metabolic features during supervised exercise 
in breast cancer patients during treatment. Our results show that breast cancer patients present 
with poor metabolic markers, body composition and fitness compared to a group of healthy 
young females at baseline. Furthermore, these patients significantly improved their plasma 
glucose and IGF-1:IGFBP-3 concentrations following 24 sessions of combined aerobic and 
resistance training. Despite the relatively small group of participants that were evaluated in this 
study, our comprehensive and integrative measurements in this population, that is challenged by 
treatment-related issues (i.e. symptoms, scheduling etc), demonstrated improvements in various 
glucose parameters. Taken together, these parameters were likely related to the 24 sessions of 
combined aerobic and strength exercise program. These findings lay the foundation for future, 
larger-scale studies that may combined this type of exercise program with an appropriate 
nutrition intervention to prevent glucose dysregulation and potentially enhance clinical and 
metabolic outcomes for breast cancer survivors.  
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7.0 General Discussion 
7.1 Improvements in breast cancer participant glucose concentrations following the exercise 
program are likely related to improved glucose clearance 
 Exercise is known to improve glucose clearance by a number of mechanisms including 
increased GLUT4 protein content and translocation (Holten et al., 2004; Hughes et al., 1993), 
increased activity of glycogen synthase (Perseghin et al., 1996), and increased muscle capillary 
density (Gavin et al., 2007) that lead to greater glucose uptake. In our study, another variable to 
consider is the fact that the majority of patients underwent treatment as well.  It could therefore 
be possible that treatment may have contributed to improvements in plasma glucose. Since the 
tumour primarily requires energy through glycolysis (Gillies et al., 2008), known as the Warburg 
effect, it is a potential mechanism for glucose clearance. Treatment is a method for eradicating 
the tumour and so, it would be expected that glucose in the circulation would rise since that 
glucose clearance mechanism has been removed. In that case, it would be the exercise then that 
improved the plasma glucose concentrations in our breast cancer patients. In contrast, studies in  
pancreatic cancer patients have shown that glucose clearance improved up to 6 weeks post- 
tumour extraction (Fogar et al., 1994). Further work is required to determine the roles of the 
tumour, treatment and exercise in glucose clearance, specifically in breast cancer patients. 
Moreover, there is limited, if any, data that exist on type or regimen of treatment and effects of 
glucose metabolism, also meriting future study.  
One methodological approach that would have aided in distinguishing the effects of 
treatment from the effects of exercise in this population, would be the use of a usual care group. 
Previous literature has demonstrated increased concentrations of insulin as well as insulin 
resistance (HOMA-IR) following adjuvant treatment (Guinan et al., 2014). Our study showed no 
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changes in insulin and a tendency to improved insulin resistance, suggesting that if a usual care 
group was included in our work, we may have been able to show that exercise mitigated the rise 
in insulin in the intended usual care group. Additionally, a retrospective study also found 
increased incidence of type 2 diabetes following treatment (Juanjuan et al., 2015). Taken 
together, it is possible that our exercise intervention not only improved plasma glucose 
concentrations but potentially prevented worsening of the metabolic profile that has been shown 
in previous studies.  
 We found that participants with greater adherence to the program (i.e. exercising 2 times 
per week for one hour and therefore, completing the program in 12 weeks), had greater 
improvements in plasma glucose concentrations. The days until program completion varied 
substantially based on patient circumstances, such as conflicts with participant medical 
appointments related to treatment and participants experiencing treatment-related side effects 
that prevented them from feeling well enough to exercise in some cases.  Despite the lengthened 
timeframe and relatively low volume of exercise, it was still impressive to observe significant 
improvements in fasting glucose.  
 
7.2 Lack of change or tendency for improvement in glucose related measures may also be a 
positive result 
 Also novel to studies examining exercise in breast cancer patients and survivors is our 
measure of c-peptide. As expected, we obtained similar results in both insulin and c-peptide. The 
measurement of c-peptide is important as it reflects insulin secretion and has a greater half-life 
than insulin, making it a reliable measure of insulin secretion (Bonser & Garcia-Webb, 1984). 
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Previous studies have also found no changes in insulin concentrations following an exercise 
intervention in breast cancer survivors (Fairey et al., 2003; Guinan et al., 2013; Schmitz et al., 
2005). Insulin and c-peptide concentrations remaining unchanged, however, may still be positive 
result seeing as these measures  often increase during the breast cancer trajectory (Guinan et al., 
2014; Ligibel et al., 2008). Still, HOMA-IR showed improvements, suggesting that insulin 
resistance was lowered with exercise training. Additionally, our results show that IGF-1 
decreased and IGFBP-3 did not change. Since IGF-1 is a known tumour proliferator and has 
been shown to increase the risk of breast cancer (Bruning et al., 1995; Peyrat et al., 1988), the 
decrease in IGF-1:IGFBP-3 ratio in our breast cancer participants post exercise training may be 
indicative of potentially preventing cancer recurrence.  
Lactate, which showed a trend for decreasing following the exercise program, could also be 
related to improvements in glucose and related markers. Diabetics have shown higher 
concentrations of lactate, potentially due to adipose tissue hypoxia and decreased skeletal muscle 
oxidative capacity (Crawford et al., 2010). This would therefore imply that improvements seen in 
aerobic capacity and presumably capillary density, both helped lower lactate production. On the 
other hand, lactate has been reviewed and described as being used for fuel and also produced by 
anaerobic glycolytic tumours (Feron, 2009). Treatment reduction in tumour size or existence 
would therefore lead to less or no anaerobic glycolysis by the tumour and therefore could be 
another reason for decreases observed in lactate concentrations. A usual care group would help 
determine whether exercise or treatment contributed to decreases in lactate. 
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7.3 Body composition, inflammatory markers, physical fitness, and dietary intake 
 A previous study that investigated a combination of unsupervised aerobic and supervised 
resistance training in breast cancer survivors also found no changes in weight or body 
composition (Ligibel et al., 2008). However, bioelectrical impedance analysis (BIA) was used 
and precision with this measure is dependent on proper preparation by the participant in terms of 
hydration and identifying the most appropriate predictive equations; although BIA may be 
practical, it may not be as reliable in cancer populations compared with other healthy populations 
(Di Sebastiano & Mourtzakis, 2012). A study comparing aerobic training to resistance training 
found that aerobic training prevented a gain of fat mass and resistance training increased the 
amount of lean mass in breast cancer survivors (Courneya et al., 2007), as identified by DXA. 
Since decreases in fat mass were not seen in other study of breast cancer survivors, it is possible 
that the increases in fat mass in our participants is due to treatment, since the majority were still 
undergoing treatment, or perhaps our training protocol was not vigorous enough to elicit any 
changes.  
Previous studies have shown that longer durations of exercise interventions result in 
greater weight loss and decreased adiposity (Neilson et al., 2009). Perhaps a longer duration of 
our exercise intervention, although potentially leading to greater challenges of participant 
retention in the program, would have yielded improvements in body composition. Additionally, 
volume, as investigated by days until program completion, did not show any significant effects 
on changes in body composition. It did, however, have an impact on fasting plasma glucose 
concentrations, showing that increased frequency of exercise sessions completed by breast 
cancer participants yielded greater improvements in fasting plasma glucose. The intensity of the 
training protocol may have shown more benefits if amplified, but then other issues such as 
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injuries may have become a problem. It is possible that we may have seen larger benefits with 
greater duration, frequency and intensity of exercise. However, our study was able to show 
improvements in blood measures and fitness even with a moderate intensity exercise protocol 
that included variable time to completion, showing that future studies should investigate varying 
exercise protocol durations, frequency and intensities that will provide optimal benefit to breast 
cancer patients. Based on our findings, even exercising sparsely (as little as one time per week 
based on the average days until program completion) is superior to not exercising at all.  
 CRP, an acute-phase inflammatory marker, has been shown to decrease the chance of 
survival in breast cancer patients (Pierce et al., 2009). Previous studies have found significant 
decreases in CRP with aerobic exercise in breast cancer survivors (Fairey et al., 2005; Guinan et 
al., 2013), although these differences were not significant when compared to a healthy young 
reference group (Guinan et al., 2013). In our case no changes were seen with exercise or between 
the breast cancer and healthy young reference groups. No differences were seen in IL-6, IL-8, 
IL-4 or IL-10 either. Perhaps no effect was seen due to a small sample size and low detection 
rate. Despite this, significant increases were seen in TNF-α and a trend for increases in IL-1β. 
High adiposity has been shown to result in elevated TNF-α through macrophages (Suganami & 
Ogawa, 2010). A study examining TNF-α mRNA in obese and normal weight women found 
higher levels of TNF-α mRNA in the obese women than the normal weight women and this was 
correlated with the level of hyperinsulinemia (Hotamisligil et al.,  1995). Reductions in weight of 
the obese females resulted in decreased TNF-α mRNA expression and improved insulin 
sensitivity, suggesting that TNF-α concentrations have an effect on insulin resistance 
(Hotamisligil et al.,  1995). Others, however, have argued that TNF-α is not related to insulin 
resistance but rather, just fat mass (Carey et al., 2004). In our study, the change in TNF-α was 
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also shown to be related to changes in fat mass but not glucose, insulin, or HOMA-IR. Again, a 
usual care group would be beneficial in order to see what changes would have occurred without 
exercise. Since cytokines are produced by various cell types, cytokines can have diverse effects 
on metabolism – some may be beneficial and others may have detrimental effects. Thus, 
interpreting our results must be done with caution. Increases in pro-inflammatory cytokines have 
been shown in the tumour microenvironment and may increase as a result of chemotherapy 
treatment (Balkwill & Mantovani, 2001; Mantovani et al., 2008).  
 As previously found in aerobic training interventions (Courneya et al., 2007; Segal et al., 
2001), our study participants showed improved aerobic capacity. A study by Kolden et al (2002) 
also found improvements in aerobic capacity with mixed aerobic and resistance exercise in a 
group-training format for breast cancer patients (where 83% were within 1 year of diagnosis). 
Additionally, the drop in resting systolic and diastolic blood pressure implies that there is less 
pressure on the arteries and that there were strength adaptations in the heart, potentially 
improving stroke volume and reducing heart rate. Improvements in strength were not observed 
consistently throughout all limbs. All limbs showed increases in strength, but significance and a 
trend was only found for the lower limbs. Though others utilizing purely strength training 
(Courneya et al., 2007; Schmitz et al., 2005) or a mixture of strength and aerobic exercise 
(Kolden et al., 2002) have found improvements in strength in breast cancer patients and 
survivors, those employing only aerobic training have not (Courneya et al., 2007). It is possible 
that for the limbs that did show improvements in strength, neural adaptations have taken place, 
allowing for increased strength without increased lean mass (Narici et al., 1989). For the limbs 
that did not improve in strength, neural changes may still be in progress or the intensity of the 
resistance training may not have been high enough to elicit significant increases in upper body 
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muscular strength. Based on a study by Coffey et al (2009), it is also possible that the anabolic 
response of resistance training was cancelled out by the aerobic training component. They 
suggest that performing both types of exercise concurrently is not optimal for allowing anabolic 
responses to take place (Coffey et al., 2009). Although all participants initiated training sessions 
with aerobic exercise, it is also possible that lean tissue did not increase due to the strength 
training focusing on muscular endurance rather than strength. Additionally, in a non-malignant 
population, anabolic goals may be in the forefront. However, in this clinical population of breast 
cancer patients, goals may not be to build muscle but rather, improve glucose metabolism. With 
the prescribed exercise program, that is exactly what was shown with decreases in fasting 
glucose concentrations and other related markers. 
It is acknowledged that the study is not without limitations. First, the sample size for the 
study is fairly small. However, it is not unusual to have small sample sizes in cancer population 
studies especially ones undergoing exercise. Our data is important for setting the foundation for 
future, more comprehensive, work. Based on our finding, future studies will know what 
measures to focus. Secondly, the breast cancer patients in our study were heterogeneous in terms 
of age, treatment type and stage. Despite the use of a heterogeneous group and the lack of a usual 
care group or an age and BMI matched non-malignant group, we were still able to see 
improvements in a number of metabolic measures. Third, exercisers on average had a long time 
to completion along with low to moderate intensity and low frequency of exercise. Despite this 
and increases in fat mass (which may mean that energy expenditure did not change much since 
dietary intake remained the same), improvements in lower body muscular strength as well as 
resting blood pressure were seen.     
! 65!
 There are many challenges in performing an exercise program in breast cancer patients 
that are undergoing treatment. For instance, the potential presence of lymphedema requires 
precautions to be taken in designing the exercise program. Additionally, different treatments may 
have diverse effects on metabolism, fatigue, pain, and appetite, all of which can affect patient 
motivation. It is important to ensure that the patients are exercising at a level that allows them to 
see metabolic benefit while also maintaining an adequate white blood cell count to avoid 
treatment delays. Last, but certainly not least, scheduling can be a major challenge in this patient 
population. Numerous medical appointments as well as acute effects of treatment felt by the 
participants can result in difficulties of exercise class attendance or scheduling of assessments. 
All of these challenges should be considered in the creation of future study designs.  
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8.0 Future Directions 
 First and foremost, the next step to this study is to recruit a group of breast cancer 
patients undergoing usual care and no exercise program. This will distinguish whether the results 
observed in this study were positively affected by exercise or by other factors. Additionally, 
larger scale, multicenter, studies should be conducted in the future. These studies will be 
expected to collect a large sample of breast cancer patients with either completely homogeneous 
groups or subgroups of patients in terms of age, stage of cancer and type and stage of treatment. 
This will help tease out potential roles of the tumour as well as treatment, while removing bias 
for culture, hospital policy etc.  
 We know that glucose clearance in breast cancer patients at the early stages of treatment, 
as measured by OGTT, is impaired (Bell et al., 2013). In order to get a deeper understanding of 
the metabolic changes that occurred with mixed aerobic and resistance training, an OGTT or, 
ideally, a euglycemic hyperinsulinemic clamp, should be performed. A euglycemic 
hyperinsulinemic clamp would be an ideal measure to include as it is the gold standard for 
measurement of insulin resistance (DeFronzo et al., 1979). However, an OGTT may be a more 
feasible start for this clinical population since this will provide us with information about glucose 
clearance in these patients without being a relatively large burden as compared with clamp 
studies.  
Based on previous literature, breast cancer patients are known to develop impairments in 
glucose metabolism (Bell et al., 2013; Can et al., 2013; Goodwin et al., 2009; Guinan et al., 
2014; Juanjuan et al., 2015; Lu et al., 2014). Literature on exact mechanisms of impaired glucose 
metabolism in the insulin signaling pathway is lacking in breast cancer patients. Identifying these 
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mechanisms as well as potential changes that happen with exercise in breast cancer patients 
would help our understanding of glucose metabolism impairments in this patient population. As 
an alternative to muscle biopsies, which are difficult to obtain, examining human muscle cells in 
vitro incubated with the blood of the participants pre and post exercise program can be used for 
analysis. Various insulin signaling protein expressions can be measured via western blotting. 
These measures will give a more comprehensive understanding of where impairments in glucose 
metabolism are taking place in breast cancer patients and how exercise may prevent these 
changes from occurring.  
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9.0 Conclusion 
 We found that breast cancer patients presented with poorer blood measures, body 
composition and fitness when compared to a young, healthy reference group. The exercise 
program completed by the breast cancer patients showed a number of positive changes including 
improvements in fasting plasma glucose and IGF-1:IGFBP-3 as well as HOMA-IR. Since 
glucose and related markers normally worsen with breast cancer treatment (Guinan et al., 2014), 
the findings in the present study may mean that the exercise program was able to prevent these 
negative outcomes. Although increases in body fat were observed, it is possible that the amount 
of fat gained was less than what would have been seen if we had a usual care group. The increase 
in fat mass was also correlated with an increase in TNF- α. Additionally, aerobic fitness 
improved as did lower body muscular strength despite no changes in lean mass. Dietary intake as 
well as macronutrient distribution remained unchanged.  
 To our knowledge, this is the first study to investigate the effects of a combined aerobic 
and resistance training program on glucose and related markers as well as body composition, 
inflammatory markers, fitness and nutrition in a group of breast cancer patients who primarily 
were still undergoing treatment. Our results show promise that the exercise program, even 
though only moderate in intensity and frequency, may lead to improvements in patients that may 
aid in preventing risk of secondary diseases.  
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Appendix II Detailed methodological descriptions of blood analysis    
Table 1 Fasting metabolic measures assessed 
Glucose Metabolism Inflammatory Markers 
Glucose TNF-α 
Insulin IL-6 
C-peptide IL-4 
HbA1c IL-8 
IGF-1 IL-10 
IGFBP-3 IL-1β 
Lactate CRP 
 
Biochemical Analysis 
Whole blood was given 30 minutes to clot at room temperature.  The blood was then 
rimmed with a plain wood applicator and centrifuged at room temperature for 15 minutes at 2500 
rpm. Following centrifugation, the serum was extracted, aliquoted into separate eppendorf tubes 
to avoid multiple thaw/re-freeze cycles, and stored at -80° C until the day of further analysis. 
Serum was collected for insulin, c-peptide, HbA1c, IGF-1, IGFBP-3, lactate, TNF-α, IL-6, IL-4, 
IL-8, IL-10, IL-1β and CRP.   
 
Plasma glucose  
Using an accu-check aviva glucose meter (Roche Diagnostics, Mississauga, ON), plasma 
glucose was measured from fresh whole blood samples. The kit used electrochemical techniques 
to determine the amount of plasma glucose. To do this, a drop of fresh whole blood collected by 
finger prick was applied to the sampling area of the test strip which was inserted in the glucose 
meter. From there, the blood moved up the tube via capillary action and then underwent 
chemical reactions with the enzyme on the strip (Mut. Q-GDH from Acinetobacter calcoaceticus, 
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recombinant in E. coli) to convert glucose to gluconolactone. The chemical reaction creates an 
electrical current that runs up the electrodes in the strip to the glucose meter where the amount of 
blood glucose is calculated based on the strength of the current (Evaluation Report, Roche 
Diagnostics, 2011). Values are calculated and converted to plasma glucose and readings of this 
value are given on the glucose meter display.   
 
Serum insulin  
Using an Insulin Specific Radioimmunoassay kit (Millipore; Etobicoke, ON), serum 
insulin was measured in duplicate.  100 µL of standard, quality controls or sample was added to 
12x75mm glass tubes. 100 µL of 125I-labeled insulin was added to all tubes followed by 100 µL 
of human insulin antibody.  The tubes were vortexed and incubated for 20-24 hours at room 
temperature.  During the 24 hour incubation, 125I-labeled insulin competed with insulin in the 
standard or sample for binding sites on the insulin antibody molecules.  Following the incubation 
period, 1.0 mL of cold (4° C) precipitating reagent was added to each tube. Tubes were then 
centrifuged for 20 minutes at 2,000-3,000 xg in order to separate the antibody-bound tracers 
from the free tracers and supernatant was aspirated from the tubes. The tubes were left with a 
small pellet, which was counted for radioactivity for 1 minute using a gamma counter (Wallac 
Wizard 1470 Automatic Gamma Counter; PerkinElmer Life and Analytical Sciences; 
Woodbridge, ON). A high concentration of insulin in the sample or standard is less radioactive 
as it will bind less 125I-labeled insulin.  
 
Serum c-peptide  
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Using a Human C-Peptide Radioimmunoassay kit (Millipore; Etobicoke, ON), serum c-
peptide was assessed in duplicate. 100 µL of standard, quality controls or sample was added to 
12x75mm glass tubes. 100 µL of 125I-labeled c-peptide was added to all tubes followed by 100 
µL of human c-peptide antibody.  The tubes were vortexed and incubated for 20-24 hours at 4°C.  
During the 24 hour incubation, 125I-labeled c-peptide competed with c-peptide in the standard or 
sample for binding sites on the c-peptide antibody molecules.  Following the incubation period, 
1.0 mL of cold (4° C) precipitating reagent was added to each tube. Tubes were then centrifuged 
for 20 minutes at 2,000-3,000 xg in order to separate the antibody-bound tracers from the free 
tracers and supernatant was aspirated from the tubes. The tubes were left with a small pellet, 
which was counted for radioactivity for 1 minute using a gamma counter (Wallac Wizard 1470 
Automatic Gamma Counter; PerkinElmer Life and Analytical Sciences; Woodbridge, ON). A 
high concentration of c-peptide in the sample or standard is less radioactive as it will bind less 
125I-labeled c-peptide.  
 
Glycated Hemoglobin (HbA1c) 
Using an A1CNow+ kit (Bayer Healthcare LLC, Sunnyvale, CA), glycated hemoglobin 
was measured from fresh whole blood samples. The kit used immunological reactions to 
determine the amount of glycated hemoglobin and a chemical reaction to determine total 
hemoglobin.  Using these values, the percentage of glycated hemoglobin was calculated.  For the 
assay, the blood collector provided with the kit used 5 µL of whole blood. Once blood was in the 
line, the blood collector was placed together with the manufacturer sampler body and shaken in 
order to dilute the sample properly.  The diluted sample was then combined with the test 
cartridge where blue microparticles bound to the anti-HbA1c antibodies and moved along 
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reagent strips until they reached the detectors. The concentration of blue microparticles present 
on the strip is equal to the total HbA1C in the sample. The sample diluent underwent a reaction 
with the hemoglobin present in the sample.  This converted hemoglobin to methemoglobin, 
which was red-brown in colour. The concentration of the red-brown colour was measured on the 
reagent strips and was representative of the concentration of hemoglobin. Finally, the monitoring 
device provided a reading of the glycated hemoglobin percentage. 
 
Serum IGF-1 
Using a commercially available human IGF-1 Quantikine ELISA kit (R&D Systems, 
Minneapolis, MN), IGF-1 was measured.  Prior to starting the assay, samples were pre-treated 
for release of IGF-1 from it’s binding protein and diluted 100-fold. The assay required 150 µL of 
Assay Diluent RD1-53 to be added to each well followed by 50 µL of sample, standard and 
control to be added to the wells coated with a monoclonal antibody specific for IGF-1. The plate 
was then be incubated for 2 hours at 2-8° C. To remove all unbound substances from the plate, 
the plate was washed.  Next, 200 µL of cold IGF-1 Conjugate was added to each well and the 
plate was incubated for 1 hour at 2-8° C. Again, the plate was washed and then, 200 µL of 
substrate solution, which bound to each IGF-1 polyclonal, was added to each well.  The plate 
was then incubated for another 30 minutes at room temperature, protected from light. 50 µL of 
stop solution was added to stop the substrate reaction in each well.  The end result was the 
formation of a yellow colour, which could be read at 450 nm, 540 nm or 570 nm.  The 
concentration of IGF-1 in the sample was directly proportional to the total signal.  
 
IGFBP-3 
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IGFBP-3 was measured using a commercially available human IGFBP-3 Quantikine 
ELISA kit (R&D Systems, Minneapolis, MN).  To start, samples were diluted 100-fold. 100 µL 
of Assay Diluent RD1-62 was added to each well followed by 100 µL of sample, standard and 
control to be added to the wells coated with a monoclonal antibody specific for IGFBP-3. The 
plate was then be incubated for 2 hours at 2-8 ° C. To remove all unbound substances from the 
plate, the plate was washed.  Next, 200 µL of cold IGFBP-3 Conjugate was added to each well 
and the plate was incubated for 2 hours at 2-8 ° C. Again, the plate was washed and then, 200 µL 
of substrate solution, which bound to each IGFBP-3 polyclonal, was added to each well.  The 
plate was then incubated for another 30 minutes at room temperature, protected from light. 50 µL 
of stop solution was added to stop the substrate reaction in each well.  The end result was the 
formation of a yellow colour, which could be read at 450 nm, 540 nm or 570 nm.  The 
concentration of IGFBP-3 in the sample was directly proportional to the total signal.  
 
Lactate 
Prior to performing the lactate assay, samples needed to undergo Perchloric Acid (PCA) 
Extraction. Extraneous proteins that may inhibit the detection of metabolites such as lactate, are 
found in serum.  In order to eliminate these extra proteins, a solution of 0.6 M perchloric acid 
was be made by mixing perchloric acid stock solution and water together.  Following this, 100 
µL of serum was combined with 500 µL of 0.6M perchloric acid in an eppendorf tube.  
Throughout the procedure, all tubes and solutions were kept on ice.  The tubes were vortexed and 
then centrifuged for 2 minutes at 4° C at 15 000g.  Following this, 250 µL of 1.25 M potassium 
bicarbonate was added to each tube which were then incubated on ice for 10 minutes and 
centrifuged once again. The resulting supernatant was transferred to new eppendorf tubes and 
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stored in the -80 °C freezer.  With the PCA extraction, a dilution factor of 8.5 was introduced 
and this was taken into account when performing calculations of final lactate concentrations.  
 Following the PCA extraction, serum lactate was measured using a 
spectroflourophotometric assay.  To start, a reagent solution was made by combining 15 mL of 
hydrazine, 15 mL glycine, and 1500 µL of NAD+ , which was then brought to a volume of 150 
mL with distilled water and a pH of 10.0 was achieved. Next, 250 uL of lactate dehydrogenase 
(Sigma-Alderich, St. Louis, MO) was combined with 1 mL of the reagent in order to dilute the 
5200 U/mL lactate dehydrogenase. Subsequently, 25 µL of dilute blank, standard, and sample 
was added to the glass test tubes in triplicate. 1mL of dilute reagent was added to each test tube 
and was vortexed.  With the absorbance set between 365 nm and 455 nm on the 
spectroflourophotometer (RF-1501; Chimadzu, Columbia, MD), baseline readings were taken. 
Following baseline readings, 25 µL of dilute lactate dehydrogenase was added to each test tube. 
Next, all tubes were vortexed and incubated for 120 minutes in the dark. A final reading was 
completed of each tube and then, the baseline readings were subtracted from the final reading in 
order to determine the final absorbency.  Lactate present in the tubes during incubation reacted 
with NAD+ to form NADH and pyruvate by the lactate dehydrogenase enzyme.  Pyruvate then 
reacted with the hydrazine found in the reagent which lead to the end of the reaction..  The 
reduction of NAD+ caused NADH to fluoresce and this is directly proportional to the 
concentration of lactate in each sample.  
 
Serum TNF-α, IL-1β, IL-6, IL-4, IL-8, IL-10 
Using the BD Cytometric Bead Array Human Soluble Protein Master Buffer Kit and BD 
FACSCalibur flow cytometer (BD Biosciences; Mississauga, ON), serum cytokines were 
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analyzed. Five types of capture beads coated with an antibody specific to TNF-α, IL-6, IL-1β IL-
4, IL-8 or IL-10 were provided in a kit.  Every bead had a corresponding detection reagent and 
this fluoresced at a specific activity.  Before starting the assay, all beads were put into one tube 
labelled ‘Mixed Capture Beads’ and then vortexed.  Detection reagents were all put into a single 
tube labelled ‘Mixed Detection Reagents’.  Lastly, the serum samples were diluted to a 1:4 ratio 
with serum diluent (from the manufacturer). 
For the assay, 50 µL of each standard or diluted sample was added to their corresponding 
tubes.  A volume of 50 µL of the Mixed Capture Beads was added to each tube and they were 
then vortexed and incubated for one hour at room temperature.  While incubating, the beads 
matched the cytokine antibodies and formed. Following incubation, 50 µL of Mixed Detection 
Reagents was added to each tube, followed by vortexing each tube and then incubating them at 
room temperature for two hours.  During incubation, a sandwich structure was formed by the 
detection reagent specific to each bead connecting with the bead/cytokine complex. Following 
incubation, each tube had 1 mL of wash buffer added to it, was vortexed and centrifuged for five 
minutes at 200g. Next, the supernatant was aspirated and the remaining pellet was re-suspended 
with 300 µL wash buffer and finally, attained on the flow cytometer.  Each of the 
bead/cytokine/detection reagent complexes had its own fluorescence.  Concentrations of each 
cytokine was determined by comparing the mean fluorescence of the populace to the standard 
curve for each cytokine.   
 
Serum C-Reactive Protein (CRP) 
Using an enzyme-linked immunoassay (ELISA) (R&D Systems, Minneapolis, MN), 
serum CRP was measured. The ELISA plate wells were pre-coated with monoclonal antibody 
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specific for human CRP.  Following addition of 100 µL of Assay Diluent RD1F to each well, 
100 µL of standard, control or sample (diluted 100-fold) was added and the plate was incubated 
for 2 hours at room temperature. In this time, CRP in the standards or samples is bound to the 
antibody-coated wells. The plate was then washed to remove all unbound substances and each 
well had 200 µL of CRP Conjugate added to it. The plate was then be incubated for 2 more hours 
during which time, the immunoconjugate was bound to the CRP-antibody complex attached to 
the wells.  Following this incubation, the plate was washed 200 µL of Substrate Solution was 
added to each well. In the dark, the plate underwent a final incubation at room temperature for 30 
minutes. 50 µL of stop solution was added to stop the substrate reaction in each well.  The end 
result was the formation of a yellow colour which could be read at 450 nm.  The concentration of 
CRP in the sample was directly proportional to the amount of colour produced.  
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Appendix III 3-day food diary 
3-Day Food Diary 
 
 
Patient ID:____________________________ 
 
 
Record Dates: DAY 1: __________ (DD/MM/YY) 
DAY 2 :___________(DD/MM/YY) 
DAY 3 :___________(DD/MM/YY) 
 
 
University of Waterloo 
Department of Kinesiology 
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Instructions for Recording Daily Food Intake 
 
          Your food diary will provide us with information on what you eat and drink during a 3-day 
period –specifically, it will help us determine the types of food and drinks, number of calories, 
amount of protein, carbohydrates, fats, and other nutrients that you consume.   
 
Instructions on how to record your information are provided below.  A ‘Sample Day: Evening 
Meal’ sheet is also provided for your reference. 
 
A) FOOD AND BEVERAGE ITEMS 
• List all the foods and beverages you consumed  
• Record the specific type of food (i.e. Whole grain bread, Shredded  
   Wheat cereal) 
• Record any items that were added in the same column (i.e. butter,  
    jam, sugar, gravy, milk, etc.) 
 
 
B) DESCRIPTION OF ITEM 
For each food or beverage item, include the following where applicable:  
! BRAND: Heinz ketchup, Chips Ahoy cookie,            
   McCain’s French fries  
! TYPE OF FLAVOUR: Vanilla ice cream, Banana muffin 
! METHOD OF COOKING: Fried rice, Baked fish, BBQ’d chicken 
! ALL RELEVANT INFORMATION ON FOOD LABEL: Low   
   fat mayonnaise, 28% M.F. marble cheese, Lean ground beef 
 
C) UNIT OF MEASURE/ NUMBER OF UNITS 
• For each food or beverage item (including toppings and/or items added), record the unit 
of measure & the number of units consumed:   
D) Examples: 1 cup of milk, 2 tablespoons of  
      garlic, 1 ½ ounces of chicken, 1 piece of cake,  
        1 teaspoon of sugar 
FILL IN BLANKS 
Please also fill in the blanks at the bottom of the record.  You will need to indicate: 
• Time of your meal or snack 
• Where your meal or snack was eaten (i.e. a restaurant, at home) 
• If you did not eat a meal or snack, please acknowledge this by placing a check mark (√) 
in the appropriate blank.  
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RECORD ALL FOODS! 
ALL foods (including toppings) and beverages you consume are important, 
whether it be a glass of water or a full course meal!   
 
PLEASE REMEMBER:  
 
1. At the end of each ‘Day’ section, please remember to complete the questions that request you 
to compare that given day with your normal diet.   
2.  Also, do not forget to fill out the last 2 pages on supplements that you are currently taking and 
the ‘Patient Generated Subjective Global Assessment’ questionnaire. 
2.  Be as accurate as possible. Please do not change your normal eating habits for the 3 days 
that you are recording your food intake.  Your honesty is crucial to the success of this research 
study.   
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SAMPLE DAY: EVENING MEAL (Dinner) 
FOOD AND 
BEVERAGE ITEMS 
DESCRIPTION OF 
ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, 
please remember to list 
each item. 
Remember to include 
details such as: 
! Brand Name 
! Flavour 
! Method of 
Cooking 
! All other 
relevant 
information on 
food/ drink 
label 
For every item, please 
indicate the unit of 
measure used and the 
number of units 
consumed. 
Spaghetti!with!tomato!sauce!
and!meatballs!
! !
Pasta!
Barilla!Pasta!Plus!spaghetti,!
cooked! 2!cups!
Tomato!Sauce!
Organic!Ragu!sauce!
(Traditional!flavour)! 1!cup!
Meat!Balls!
Made!with!President’s!
Choice!extra!lean!ground!
beef! 5!(1oz/ball)!
Parmesan!cheese! Kraft,!30%!Milk!Fat!(M.F.)! 1!tablespoon!
Cheesy!Garlic!Bread!
McCain’s!garlic!fingers!(with!
cheese)! 2!pieces!
Caesar!Salad!
! !Lettuce! Romaine! 1!cup!
Croutons!
Pepperidge!Farm!classic!cut!
seasoned!croutons! 2!tablespoons!
Salad!Dressing! Kraft,!Ranch,!Fat!Free! 2!tablespoons!
Orange!Juice!
Tropicana,!No!Pulp,!100%!
Vitamin!C! 1!cup!
Cheesecake!
President’s!Choice!Red!
Velvet!cheesecake! 1/10th!of!cake!
Coffee! Gevalia!Black!Iced!Coffee! 1!cup!
FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
!
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DAY!1:!MORNING!MEAL!(Breakfast)!
FOOD!AND!BEVERAGE!ITEMS! DESCRIPTION!OF!ITEM! NUMBER!OF!UNIT!MEASURES!
!
Include!ALL!food!and!beverage!items!
consumed.!!For!combination!foods,!
please!remember!to!list!each!item.!
Remember!to!include!
details!such!as:!
! Brand!Name!
! Flavour!
! Method!of!
Cooking!
! All!other!
relevant!
information!
on!food/!
drink!label!
For!every!item,!please!indicate!
the!unit!of!measure!used!and!the!
number!of!units!consumed.!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
! ! !FILL$IN$THE$BLANKS:$$$
Time!of!meal/snack:!________________!!!!!!!!Location!meal/snack!was!consumed:!
________________!
Please!CHECK!(√)!if!you!did!not!eat!or!drink!at!this!meal!or!snack!time:!!____!
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DAY 1: MID-MORNING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 1: MID-DAY MEAL (Lunch) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 1: MID-AFTERNOON SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 1: EVENING MEAL (Dinner) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 1: EVENING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 1 MEALS 
Compared to my normal diet, I ate: 
 
 
o The same amount as I would usually eat  
 
o  More than I would usually eat     
o  Less than I would usually eat  
 
o Please circle how you felt today for each of the symptoms below: 
 
0     1     2     3     4     5     6     7      8      9     10 
    Best Appetite                                                           Worst Possible Appetite 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Nauseated                                                        Worst Possible Nausea 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Tired                                                                  Worst Possible Tiredness 
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DAY!2:!MORNING!MEAL!(Breakfast)!
FOOD!AND!BEVERAGE!ITEMS! DESCRIPTION!OF!ITEM! NUMBER!OF!UNIT!MEASURES!
!
Include!ALL!food!and!beverage!items!
consumed.!!For!combination!foods,!
please!remember!to!list!each!item.!
Remember!to!include!
details!such!as:!
! Brand!Name!
! Flavour!
! Method!of!
Cooking!
! All!other!
relevant!
information!
on!food/!
drink!label!
For!every!item,!please!indicate!
the!unit!of!measure!used!and!the!
number!of!units!consumed.!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
! ! !FILL$IN$THE$BLANKS:$$$
Time!of!meal/snack:!________________!!!!!!!!Location!meal/snack!was!consumed:!
________________!
Please!CHECK!(√)!if!you!did!not!eat!or!drink!at!this!meal!or!snack!time:!!____!
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DAY 2: MID-MORNING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 2: MID-DAY MEAL (Lunch) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 2: MID-AFTERNOON SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 2: EVENING MEAL (Dinner) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 2: EVENING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 2 MEALS 
Compared to my normal diet, I ate: 
 
 
o The same amount as I would usually eat  
 
o  More than I would usually eat     
o  Less than I would usually eat  
 
o Please circle how you felt today for each of the symptoms below: 
 
0     1     2     3     4     5     6     7      8      9     10 
    Best Appetite                                                           Worst Possible Appetite 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Nauseated                                                        Worst Possible Nausea 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Tired                                                                  Worst Possible Tiredness 
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DAY!3:!MORNING!MEAL!(Breakfast)!
FOOD!AND!BEVERAGE!ITEMS! DESCRIPTION!OF!ITEM! NUMBER!OF!UNIT!MEASURES!
!
Include!ALL!food!and!beverage!items!
consumed.!!For!combination!foods,!
please!remember!to!list!each!item.!
Remember!to!include!
details!such!as:!
! Brand!Name!
! Flavour!
! Method!of!
Cooking!
! All!other!
relevant!
information!
on!food/!
drink!label!
For!every!item,!please!indicate!
the!unit!of!measure!used!and!the!
number!of!units!consumed.!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
!! !! !!
! ! !FILL$IN$THE$BLANKS:$$$
Time!of!meal/snack:!________________!!!!!!!!Location!meal/snack!was!consumed:!
________________!
Please!CHECK!(√)!if!you!did!not!eat!or!drink!at!this!meal!or!snack!time:!!____!
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DAY 3: MID-MORNING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 3: MID-DAY MEAL (Lunch) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 3: MID-AFTERNOON SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
 
! 116!
DAY 3: EVENING MEAL (Dinner) 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 3: EVENING SNACK 
FOOD AND BEVERAGE 
ITEMS DESCRIPTION OF ITEM 
NUMBER OF UNIT 
MEASURES 
 
Include ALL food and 
beverage items consumed.  
For combination foods, please 
remember to list each item. 
 
Remember to include details 
such as: 
! Brand Name 
! Flavour 
! Method of Cooking 
! All other relevant 
information on 
food/ drink label 
 
For every item, please 
indicate the unit of measure 
used and the number of units 
consumed.  
 
      
      
      
      
      
      
      
      
      
      
      
      
   
   FILL IN THE BLANKS:   
Time of meal/snack: ________________        Location meal/snack was consumed: 
________________ 
Please CHECK (√) if you did not eat or drink at this meal or snack time:  ____ 
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DAY 3 MEALS 
Compared to my normal diet, I ate: 
 
 
o The same amount as I would usually eat  
 
o  More than I would usually eat     
o  Less than I would usually eat  
 
o Please circle how you felt today for each of the symptoms below: 
 
0     1     2     3     4     5     6     7      8      9     10 
    Best Appetite                                                           Worst Possible Appetite 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Nauseated                                                        Worst Possible Nausea 
 
0     1     2     3     4     5     6     7      8      9     10 
    Not Tired                                                                  Worst Possible Tiredness 
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Appendix IV 3-day food diary results 
Table 1 Dietary intake  
 Baseline of 
breast cancer 
dropouts 
(n=7) 
Baseline of 
breast cancer 
exercise 
completers 
(n=15) 
Post-
assessment of 
breast cancer 
exercise 
completers 
(n=15) 
Young, Healthy 
Females (n=10) 
Caloric Intake 
(kcal) 
1885 ± 328 1718 ± 358 1729 ± 410 2262 ± 578 
Protein (%) 18 ± 2 17 ± 3 17 ± 4 20 ± 6 
Fat  (%) 35 ± 4 34 ± 6 34 ± 8 31 ± 9 
Carbohydrate  
(%) 
49 ± 3 51 ± 7 50 ± 9 52 ± 8 
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Appendix V Power calculations 
Table 1 Power and sample size calculations for changes seen in glucose and related measures 
Measure Mean change from 
baseline to post-
exercise program ± 
SD 
(n=15) 
Power Sample size 
required to achieve 
80% power  
Plasma glucose 
(mM) 
-0.4 ± 0.5 0.822 15 
Insulin (uIU/mL) -2.1 ± 5.2 0.306 51 
C-peptide (ng/mL) -0.3 ± 2.2 0.087 324 
HOMA-IR -0.7 ± 1.4 0.472 31 
IGF-1 (ng/mL) -21.6 ± 41.0 0.475 31 
IGFBP-3 (ng/mL) 8.8 ± 61 0.082 381 
IGF-1:IGFBP-3 -0.61 ± 0.9 0.704 19 
Lactate (mM) -0.8 ± 1.5 0.460 32 
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Table 2 Power and sample size calculations for changes seen in body composition measures 
Measure Mean change from 
baseline to post-
exercise program ± 
SD 
Power Sample size 
required to achieve 
80% power  
Weight (kg) 0.7 ± 2.6 (n=15) 0.162 113 
BMI (kg/m2) 0.2 ± 0.9 (n=15) 0.122 159 
WC (cm) -1.1 ± -4.5 (n=15) 0.146 130 
Appendicular lean 
muscle mass (kg/m2) 
-0.1 ± 0.4 (n=14) 0.149 117 
% fat 1.7 ± 2.7 (n=14) 0.570 23 
Total fat mass (kg) 1.5 ± 2.6 (n=14) 0.529 25 
Total lean mass (kg) -0.9 ± 2.0 (n=14) 0.351 40 
Total lean mass in 
limbs (kg) 
-0.2 ± 1.0 (n=14) 0.081 356 
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Table 3 Power and sample size calculations for changes seen in fitness measures 
Measure Mean change from 
baseline to post-
exercise program ± 
SD (n=14) 
Power Sample size 
required to achieve 
80% power  
Right leg extension 
(Nm) 
7.2 ± 14.2 0.422 33 
Left leg extension 
(Nm) 
14.7 ± 22.4 0.620 21 
Right & left leg 
extension (Nm 
24.1 ± 34.9 0.666 19 
Right arm flexion 
(Nm) 
2.3 ± 5.0 0.349 41 
Left arm flexion 
(Nm) 
2.3 ± 6.6 (n=13) 0.280 69 
Right and left arm 
flexion (Nm) 
4.5 ± 10.4 (n=13) 0.303 44 
Predictive VO2 
(mL/kg/min) 
2.4 ± 3.3 (n=13) 0.654 18 
Resting heart rate 
(bpm) 
-1.4 ± 9.4 0.083 340 
Systolic blood 
pressure (mmHg) 
-6.0 ± 6.6 0.867 12 
Diastolic blood 
pressure (mmHg) 
-4.3 ± 8.7 0.401 35 
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Table 4 Power and sample size calculations for changes seen in inflammatory markers 
Measure Mean change from 
baseline to post-
exercise program ± 
SD 
Power Sample size 
required to achieve 
80% power  
CRP (mg/L) 0.01 ± 0.19 (n=15) 0.051 12099 
TNF-α (pg/mL) 1.2 ± 0.9 (n=7) 0.853 7 
IL-8 (pg/mL) 2.1 ± 4.4 (n=13) 0.361 36 
IL-6 (pg/mL) 1.8 ± 5.3 (n=7) 0.117 73 
IL-1β (pg/mL) 0.9 ± 1.3 (n=8) 0.385 19 
IL-4 (pg/mL) 0.5 ± 1.3 (n=7) 0.156 47 
IL-10 (pg/mL) -0.1 ± 1.4 (n=13) 0.058 1197 
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Table 5 Power and sample size calculations for changes in dietary measures 
Measure Mean change from 
baseline to post-
exercise program ± 
SD (n=15) 
Power Sample size 
required to achieve 
80% power  
Caloric intake (kcal) 11 ± 265 0.052 5027 
Protein (%) -0.6 ± 5.3 0.070 596 
Fat (%) -0.5 ± 7.4 0.058 1419 
Carbohydrate (%) -0.2 ± 9.0 0.051 17287 
 
 
